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The majority of new HIV infections in women are transmitted through vaginal intercourse 
where the female genital tract (FGT) functions as the portal of viral entry. The aim of this 
thesis was to characterize mucosal factors within the FGT to better understand potential 
molecular mechanisms associated with altered HIV-susceptibility. 
The vaginal microbiome and the menstrual cycle are associated with altered 
HIV-susceptibility, but their collective impact on the cervicovaginal milieu remains largely 
unknown. In Paper 1, we studied healthy, Swedish women and observed the largest changes 
of the genital proteome during the estradiol-dominated ovulatory phase. This phase was 
characterized by a decrease in neutrophil-associated proteins and pathways and an increase in 
epithelial barrier-promoting proteins, as compared to the progesterone-dominated luteal 
phase. Menstrual cycle-related changes in epithelial barrier proteins were enhanced in women 
with a non-Lactobacillus dominated vaginal microbiome. This study showed that female sex 
hormones modulated genital inflammation and epithelial barrier function and that these 
changes were further impacted by the vaginal microbiome. 
Semen can induce an inflammatory response in the FGT, but its role in HIV-
transmission is largely unknown and limited due to a lack of adequate experimental models. 
In Paper 2, we used a genital tissue explant model to show that seminal plasma induced 
genital inflammation and increased HIV-infectivity, highlighting the importance of 
including seminal plasma as a factor in HIV-transmission studies. The genital tissue explant 
model used in this study could also be suitable for studying HIV-transmission and 
evaluation of microbicides. 
Studies in female sex workers (FSWs) at high risk of HIV-infection reveal 
alterations in the genital mucosal milieu. In Paper 3, we used a high-throughput bead-based 
affinity set-up to evaluate protein expression in genital secretions of another cohort at risk 
of HIV-infection, namely Kenyan HIV-seronegative women living in HIV-serodiscordant 
relationships. As compared to HIV-seronegative women in HIV-seroconcordant 
relationships, we found alterations in genital proteins involved in inflammation and 
epithelial barrier remodeling pathways. Such phenotype was observed despite low levels of 
clinical inflammation and high levels of safe sex practices in this cohort. These results 
suggest that women in HIV-serodiscordant relationships have a unique cervicovaginal 
environment, and that this may be associated with an altered susceptibility to HIV infection. 
However further studies would be required to fully elucidate the relationship between the 
observed phenotype and HIV infection risk. 
Observational and experimental studies indicate that use of the injectable 
progestin-based contraceptive depot medroxyprogesterone acetate (DMPA) is associated 
with increased risk of HIV. In Paper 4, we revealed a transcriptional profile consistent with 
impaired epithelial integrity and increased immune activation in ectocervical tissues from 
Kenyan FSWs using DMPA. In situ-based imaging analysis revealed a thinner superficial 
epithelial layer and an altered distribution of potential HIV-target cells. Collectively, these 
results suggest that DMPA may weaken the epithelial barrier and contribute to increased 
HIV-susceptibility. 
In summary, female sex hormones, living in a HIV-serodiscordant 
relationship and seminal factors induce changes in the FGT that may alter HIV-
susceptibility. Endogenous and exogenous progesterone/progestins reduce epithelial barrier 
integrity and induce cervicovaginal inflammation. The knowledge gained from these 
studies can help guide the development of safe contraceptive methods. The aforementioned 
factors must be taken into consideration when designing and interpreting results from 
clinical studies in the HIV-prevention field, and can also help guide the development of 
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1.1 INTRODUCTION TO HIV/AIDS 
1.1.1 Discovery of HIV/AIDS 
 
In 1981, the first case report of five previously healthy, homosexual young men presenting 
with Pneumocystis carinii pneumonia was published (1). The report concluded that "The 
above observations suggest the possibility of a cellular-immune dysfunction related to a 
common exposure that predisposes individuals to opportunistic infections." In the following 
year, additional cases of young, homosexual men and intravenous drug users with 
opportunistic infections and Kaposi’s sarcoma were identified, and this group of symptoms 
were called acquired immunodeficiency syndrome (AIDS) (2). The etiology of AIDS was 
in 1983 discovered to be a virus that would later be named Human Immunodeficiency 
Virus (HIV)-1 (3, 4), a discovery that resulted in the Nobel Prize in Medicine and 
Physiology in 2008. In the beginning of the epidemic, HIV was primarily spread in men 
who have sex with men (MSM) populations, but today the global epidemic is 
predominately heterosexual in nature, even though certain populations, including MSM, 
counts for a significant part of the burden in some countries (5). There are two types of the 
virus, HIV-1 and HIV-2, but the vast majority of cases worldwide are caused by HIV-1, 
which will here be referred to as HIV. 
1.1.2 The HIV epidemic 
 
Since 1980’s, HIV has spread across the world, and WHO estimates that 39.5 million 
people were infected with HIV in 2018 (6). Sub-Saharan Africa bears a disproportionate 
HIV-burden, and an estimated 65% (25.7 million) of HIV-infected individuals live in 
Africa (6). Global incidence rates have been declining since the late 1990’s, but despite 
this, a staggering 1.7 million people were newly infected with HIV in 2018, 61% of these in 
sub-Saharan Africa (6). In 2014, the United Nations Programme on HIV/AIDS (UNAIDS) 
launched ambitious treatment targets called “90-90-90”, stating that by 2020, 90% of HIV-
infected individuals will know their HIV status, 90% of all HIV-diagnosed individuals will 
be on sustained antiretroviral therapy (ART), and that 90% of individuals receiving ART 
will have viral suppression (7). However, only 60 of the 170 countries included in the 
annual report by UNAIDS reached all three targets in 2018, and many countries are 
considered unlikely to reach the targets by 2020 (8). Globally so far, 79% of HIV-infected 
individuals know their HIV-status and of these, 78% are on ART, and 86% of these show 
viral suppression (8). 
 
1.1.2.1 HIV in Kenya 
 
The East African nation of Kenya is one of the most affected countries by the HIV 
epidemic, and will be discussed here since two cohorts in this thesis are Kenyan. The adult 
HIV-prevalence in Kenya peaked at 10-11% in the mid 1990’s (9), and has now declined to 
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an estimated 4.7% in 2018 as compared to a global prevalence of 0.8% (6). The HIV 
incidence has declined from 6.2 to 1.02 per 1000 in year 2000 and 2018, respectively (6, 9). 
Despite such advances of decreased prevalence and incidence rates, 46, 000 individuals are 
newly infected each year (6). UNAIDS has identified key populations at especially high 
risk for HIV-infection, including sex workers, MSM, transgender women and intravenous 
drug users (6). In Eastern and Southern Africa, key populations and their sexual partners 
account for an estimated 25% of new HIV-infections. In Kenya, the HIV burden among 
female sex workers (FSWs) remains very high with an estimated HIV-prevalence of 29% in 
2011 (10), with no more recent estimates available. Reasons for such high prevalence in 
FSWs include work-related, including sexual violence, inability to negotiate safe sex 
practices, criminalization of sex work as well as stigma and discrimination (5). By focusing 
on reducing such factors, HIV-transmission within this group, and subsequently within the 
general population, may decrease. 
1.1.3 Transmission of HIV 
 
HIV is spread by three main modes of transmission: sexual, parenteral and vertical (mother- 
to-child), and heterosexual transmission is the most common mode globally (5). Estimated 
transmission rates vary widely between the different modes of transmission and also 
between different studies. A meta-analysis estimate the risk of HIV-acquisition for an HIV-
negative woman during vaginal intercourse with an HIV-positive man without ART to 
0.08-0.30% per sexual act (11). The risk of HIV-acquisition during receptive anal 
intercourse is substantially higher, estimated at 1.7% per sexual act (11). However, the risk 
of sexual transmission depends on many other factors in addition to type of sexual practice, 
such as plasma viral load (12, 13), concordant or recent sexually transmitted infections 
(STIs) and/or genital inflammation (14-18), genital ulcering (12, 17), cervicovaginal 
microbiota composition (19), male circumcision (20, 21) and use of hormonal 
contraceptives (HC) (22-24). 
1.2 DEFENSES AGAINST HIV IN THE FEMALE GENITAL TRACT 
 
The female genital tract (FGT) can be divided into the lower (ectocervix and vagina) and 
upper (ovaries, fallopian tubes, uterus, endocervix) FGT. The lower FGT is lined by a 
multilayer squamous epithelium, whereas the endometrium and endocervix of the upper 
FGT is covered by a single-layered columnar epithelium. The lower FGT is the first site of 
contact for HIV transmitted through vaginal intercourse, and the complex defense 
mechanism of the FGT against HIV include both anatomical (the mucus layer and 




Figure 1. Schematic representation of the epithelium in the female genital tract and suggested 
mechanisms for heterosexual transmission of HIV. The ectocervix and vagina of the lower female genital 
tract are lined by a multilayer, stratified squamous epithelium, providing a physical barrier preventing 
the virus from entering the body. Proposed mechanisms for how the virus can traverse the epithelium is 
through microabrasions in the epithelium or by uptake by intraepithelial Langerhans cells. 
1.2.1 Anatomical barriers to HIV: mucus and the epithelium 
 
In order to establish an infection, the virus must traverse the epithelium of the FGT to reach 
susceptible HIV-target cells in the epithelium and/or submucosa. Once a small population 
of HIV-infected cells has been established in the submucosa, the virus is eventually spread 
to the draining lymph nodes through the lymphatic system (25). In the lymph nodes, 
massive viral replication occurs and the infection is subsequently disseminated in the body. 
 
However, first the virus and/or virally infected cells must overcome several anatomical 
barriers. A layer of mucus, produced primarily by endocervical cells, line the epithelium of 
the cervix and vagina and can provide protecting against HIV by physically trapping virions 
and seminal cells (26, 27). The mucus lining the endocervix is thicker and more viscous 
than the mucus lining the ectocervix and vagina, where the mucus from the endocervix is 
mixed with vaginal fluid. Additionally, commensal bacteria, usually dominated by 
Lactobacillus, line the epithelial cells and contribute to an acidic and anti-inflammatory 




The epithelium underneath the mucus layer forms an additional physical barrier that hinders 
the virus from reaching target cells and submucosa. The epithelium of the lower FGT is a 
non-keratinized stratified epithelium that consists of several layers of keratinocytes that 
undergo programmed differentiation from the basal membrane to the most apical layer 
before being exfoliated into the vaginal lumen. The nomenclature of the layers within the 
epithelium varies between studies, but it is usually considered to consist of three layer: the 
stratum basale/parabasal layer, the suprabasal/intermediate layer and the stratum 
corneum/superficial layer (30). The thickness of the vaginal and ectocervical epithelium 
varies but is approximately 150-500 µm and consists of 25-30 cell layers (31-34). The 
keratinocytes of the stratified epithelium are held together by cell junctions such as tight 
junctions, adherence junctions and desmosomes, contributing to the barrier function of the 
epithelium (33, 35-37). The intact squamous epithelium of the vagina/ectocervix is more 
robust against HIV-invasion than the columnar epithelium of the endocervix, but the 
surface area of the vagina/ectocervix is more than 15 times that of the endocervix, and the 
relative contribution of the different sites in establishing initial infection is not known (38). 
The transformation zone, where the columnar epithelium of the upper FGT meets the 
squamous epithelium of the lower FGT, is rich in immune cells (including HIV target cells) 
(39), indicating that this area could be especially susceptible to HIV. 
 
Several mechanisms of how HIV crosses the epithelium have been proposed, such as for 
the single columnar epithelium of the upper FGT: i) transcytosis/endocytosis of the virus 
across the epithelium, ii) transmigration of the virus or iii) translocation by dendritic cells 
(40, 41). To cross the multilayer squamous epithelium of the lower FGT, the virus and/or 
virally infected cells have been suggested to transmigrate through micro-abrasion in the 
epithelium and/or by uptake of the virus by intraepithelial Langerhans cells (LC) (see 
section on HIV target cells below). Furthermore, Carias et al. demonstrated in cervical 
explants that HIV virions could penetrate intact squamous epithelium and passively diffuse 
up to 50 µm, but most virions did not diffuse past 10 µm in both ectocervical and 
endocervical tissues (36). Interestingly, when disrupting cellular junctions, more virus 
penetrated the tissues and to greater depths, indicating that intact cellular junctions hinder 
passive diffusion of the virus. In addition, in an in vitro model of monolayer genital 
epithelial cells, exposure to HIV disrupted tight junctions and increased permeability of the 
epithelium, allowing virus entry (42). The importance of epithelial thickness has been 
clearly demonstrated in non-human primate models, where a thin epithelial lining 
(following progestin treatment) greatly enhances simian immunodeficiency virus (SIV) 
transmission (43). However, the exact mechanisms of HIV transmission in humans and the 
effect of the thickness and integrity of the epithelium as such remain largely unknown. 
1.2.2 Biological barriers to HIV: antimicrobial factors and immune cells 
 
Cervicovaginal secretions (CVS) bathes the lining of the lower FGT and is composed of a 
mixture of plasma transudate, fluid originating from the upper FGT, cervical mucus, 
secretion from serous cells in submucosal glands, and secretions from immune and 
epithelial cells (44). The composition of CVS is dependent on several factors such as the 
menstrual cycle (45-48), use of HC (49, 50), genital inflammation (51) and the 




Antimicrobial peptides (AMPs) are small proteins of the innate immune system that have 
broad anti-microbial effects against many pathogens, including HIV. CVS contain several 
AMPs secreted from immune and epithelial cells, such as human a and b-defensins and the 
cathelicidin LL-37 (53-57) with anti-HIV activity in vitro (58). A study by Venkataraman 
et al. demonstrated anti-HIV activity only when combining several AMPs at physiological 
concentrations, suggesting AMPs have a synergetic effect on HIV neutralization (59). 
However, despite such anti-HIV activity in vitro, the protective role of AMPs against HIV 
in vivo remains unclear (58). Some AMPs are even associated with increased risk for HIV-
acquisition (60, 61), presumably by recruiting HIV target cells to the mucosa. Additional 
proteins in genital secretions are emerging as having potential protective roles against HIV, 
such as the proteins SLPI and PI3/elafin as well as other anti-proteases, especially serine 
protease inhibitors (serpins) (57, 59, 62-64). However, it seems as if it is the combined 
effect of proteins/AMPs on the genital mucosa, rather than individual components, that 
modulate HIV-susceptibility (58, 65, 66). 
 
There is an abundance of innate immune cells in the FGT that contribute to the defense 
against HIV. They recognize pattern associated molecular patterns, such as HIV single-
stranded ribonucleic acid (RNA) or the surface glycoprotein (gp) 120 on the HIV viral 
particle (67, 68), triggering the release of pro-inflammatory cytokines and the promotion of 
an antiviral environment (69). Importantly, both immune and epithelial cells produce 
numerous cytokines/chemokines and AMPs with important immunomodulatory roles (70, 
71), such as recruitment of additional immune cells (72, 73). However, the presence of 
immune cells in the FGT is a double-edged sword since some immune cells can also 
function as early target cells for HIV (74). 
1.2.2.1 HIV target cells in the FGT 
 
In order to enter a target cells, the surface molecule gp120 on the HIV-virus binds to a 
cluster of differentiation (CD) 4 receptor on the target cell, inducing a conformational 
change allowing the binding to one of the co-receptors for HIV, mainly CC chemokine 
receptor (CCR) 5 and CXC chemokine receptor 4. This causes the gp41 protein on the viral 
surface to penetrate the plasma membrane, allowing viral fusion and penetration of the host 
cell. HIV-strains that utilize the CCR5 and CXC chemokine receptor 4 coreceptors are 
referred to as “R5” or “X4” tropic strains, respectively. Despite the fact that blood, semen, 
CVS and rectal secretions contain both R5 and X4 tropic strains, in general only R5 strains 
are responsible for primary transmission events (75). 
 
CD4+ T-cells in the FGT are considered the main target cells for the HIV virus (76, 77), and 
recent studies have identified subsets of CD4+ T-cells, namely T-helper 17 cells (Th17) and 
cells expressing the integrins a4b7 or a4b1, that seem especially susceptible to the virus (78, 
79). CD4+ T-cells in the FGT are mainly infected through the CD4/CCR5 receptors. CD4+ 
T-cells are located in the epithelium and in the underlying submucosa in the FGT (80, 81). 
 
Other HIV-target cells in the FGT include macrophages and dendritic cells (DC), including 
a subset of DC called LC (82-84). These cells express CD4 and CCR5, and also, to varying 
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degrees depending on subtype, C-type lectin receptors such as DC-SIGN, Langerin and 
Mannose-receptor, that can functions as receptors for the virus (85-87). However, the 
consequences of HIV uptake via the different receptors may differ (85, 88). Intra-epithelial 
LC reside within the female genital epithelium (82), and are considered to be one of the 
first cells that encounter the virus and can pass on the virus to CD4+ T-cells (89). HIV can 
also be degraded in Birbeck granules in LC, but a recent study demonstrated that LC in the 
FGT do not harbor Birbeck granules and that infection of vaginal LC sustained productive 
HIV-infection (90). Other subtypes of DC and macrophages reside mainly in the 
submucosa, and can facilitate CD4+ T-cell infection (85) and be productively infected by 
HIV ex vivo (91), respectively. 
1.3 FACTORS THAT INFLUENCE HIV SUSCEPTIBILITY IN THE FGT 
 
Mucosal inflammation, female sex hormones and the cervicovaginal microbiome can 
influence HIV susceptibility in the FGT, as discussed below. 
1.3.1 Mucosal inflammation 
 
Inflammation is the body’s response to noxious stimuli, such as foreign pathogens, and 
hallmarks of inflammation include secretion of cytokines and accumulation of immune 
cells. However, genital inflammation, as defined by elevated mucosal 
cytokines/chemokines, has been associated with increased HIV acquisition (14, 92-94). 
Several cytokines are chemotactic to HIV target cells (71, 95, 96), and one potential 
mechanism for increased HIV susceptibility is an accumulation of such cells in genital 
tissues (51, 97). Furthermore, the pro-inflammatory cytokine TNFa can disrupt tight 
junction proteins in the epithelial barrier, contributing to decreased epithelial barrier 
integrity and increased access of the virus to target cells (42). Elevated mucosal pro-
inflammatory cytokines have also been shown to be associated with a proteomic signature 
of neutrophil accumulation, a weakened epithelial barrier and elevated levels of genital 
HIV-target cells (51). In addition to the evidence that increased inflammation enhances 
HIV susceptibility, reduced genital inflammation has been associated with protection to 
HIV (see section 1.4.1), further emphasizing the role of inflammation in HIV-transmission. 
However, the exact mechanisms of how genital inflammation affects the genital epithelium 
and/or HIV susceptibility are far from well characterized. 
1.3.1.1 Semen-induced mucosal inflammation 
 
As mentioned previously, the vast majority of new HIV-infections are transmitted through 
heterosexual intercourse, where the virus and/or infected cells in semen are deposited in the 
vagina. Exposure to semen in the FGT is associated with a so called “leukocytic reaction”, 
characterized by a pro-inflammatory response with an influx of immune cells, most notably 
neutrophils, in the cervix (98, 99). This was originally characterized in cervical smears after 
artificial insemination, but unprotected coitus also leads to increased expression in 
ectocervical biopsies of several pro-inflammatory genes as well as influx of leukocytes to 
the mucosa (100). Interestingly, the observed leukocyte influx was not seen with protected 
coitus, indicating that it is the mucosal reaction to the semen itself and not the mechanical 
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effect of coitus that causes such phenotype. However, another study assessing genital 
secretions after unprotected intercourse did not observe a general increase in cytokines 
(101). In addition, studies on the effect of semen in the FGT are complicated since 
incubation with semen and/or seminal plasma can induce toxicity in isolated cells (102, 
103). Recent studies have investigated the role of semen in HIV-transmission (reviewed in 
(104)), suggesting that, although somewhat contradictory results, the effect of semen can 
modulate the genital micro-environment as to cause enhanced susceptibility to HIV. 
However, the effect of semen of the female genital mucosa needs further studies, especially 
on how semen-induced inflammation affects HIV-transmission. 
1.3.2 Female sex hormones 
 
It has been suggested that the menstrual cycle and HC affect HIV susceptibility and that 
this might be a result of alterations in endogenous and exogenous female sex hormones (45, 
105-113). This effect is therefore described in further detail below. 
1.3.2.1 The menstrual cycle 
 
The cyclic changes in the FGT over the menstrual cycle are essential for reproduction and 
are governed by the fluctuations of the ovarian sex hormones estradiol and progesterone. 
These fluctuations are under the control of the complex hypothalamic-pituitary-gonadal 
axis. Very briefly, the pulsatile release of gonadotropin-releasing hormone (GnRH) from 
the hypothalamus regulates the secretion of luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) from the anterior pituitary gland (114). LH and FSH affects the 
production of the female sex hormones estradiol and progesterone in the ovaries, which in 
turn exert feedback loops, both positive and negative, at the pituitary and hypothalamic 
level in a complex feedback system. 
 
The menstrual cycle can be divided into different phases/stages depending on if referring to 
the ovarian or the uterine cycle (Figure 2). The uterine cycle can be divided into menses, 
the proliferative and the secretory phase, whereas the ovarian cycle consists of the 
follicular, mid-cycle/periovulatory and the luteal phase. In this thesis, the terms follicular, 





Figure 2. Hormonal fluctuations over the menstrual cycle. The cyclic changes in female sex hormones 
levels in serum over a classical 28-day menstrual cycle. FSH: follicle stimulating hormone, LH: 
luteinizing hormone. Figure created using Biorender.com. 
1.3.2.2 The phases of the menstrual cycle 
 
The follicular phase is the period between the initiation of bleeding/menses until ovulation. 
During menses, the functional layer of the endometrium is sloughed off and the levels of 
estradiol and progesterone are low, stimulating the increased secretion of GnRH, LH and 
FSH (114). FSH from the anterior pituitary gland stimulates the follicular cells in the 
ovaries to produce estradiol. Estradiol stimulates the proliferation of the endometrium, 
including growth of all tissue components such as glands, stromal and endothelial cells. The 
spiral arteries lengthen as the endometrium is re-established and at the end of the follicular 
phase, these arteries are slightly coiled. The high levels of estradiol stimulate a surge in LH 
secretion, and this LH-surge triggers ovulation in the ovaries. The luteal phase is the period 
between ovulation until the start of next menstrual bleeding. The remaining follicle after 
ovulation is transformed into the corpus luteum that produces progesterone and estradiol. 
Peak progesterone and estradiol levels are reached at approximately 8 days after ovulation 
(115). Progesterone stimulates the endometrium to develop spiral vessels that lengthen and 
become more coiled, enlargement of glands that become corkscrew shaped as well as tissue 
edema (116). In the late luteal phase, leukocytes infiltrate the endometrium (116, 117). If 
no fertilization occurs, the corpus luteum degenerates and levels of progesterone and 
estradiol decrease rapidly, initiating menstruation.  
1.3.2.3 Variation in length of the menstrual cycle 
 
Menstrual cycle length is the interval from the first day of menses up to and including the 
day before subsequent menses. There is large inter- and intra-individual variation in 
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menstrual cycle length between women (118, 119), but a menstrual cycle between 21 and 
35 days in length is usually considered normal (reviewed in (120)). A large study in 
American women from 1967 demonstrated an average menstrual cycle length of 28 days in 
women between the ages of 20-40, and that menstrual cycles successively shorten after 20 
years of age (121). Similar results have been found in more recent studies (118, 122). 
However, only 10-15% of cycles in reproductive aged women are actually 28 days in length 
(115, 119). A recent study of >600, 000 ovulatory menstrual cycles based on data from a 
digital fertility awareness application showed that 13% of cycles were 28 days in length, 
and that 26% of cycles were 31 days or longer (123). In general, the greatest variability in 
length is in the follicular phase (115, 119). Traditionally it was believed to be little variation 
in length of the luteal phase (approx. 14 days) because of the set duration of the survival of 
the corpus luteum, but studies have observed luteal phase lengths between 7-19 days (119, 
120, 124). 
1.3.2.4 The menstrual cycle and HIV susceptibility 
 
An increased susceptibility to simian-HIV/SIV during the late luteal/menstrual phase has 
been observed in non-human primates (105, 106, 125). Furthermore, in cervical explants, 
productive HIV-infection was only observed in tissues donated from women in the luteal 
phase of the menstrual cycle (113), but this has not been seen by others (126). Wira et al. 
observed that several aspects of the innate and adaptive immune system in the FGT are 
suppressed 7-10 days post ovulation in order to facilitate procreation, and they hypothesize 
that this creates a so called “Window of vulnerability” during which women are more 
susceptible to HIV and other STIs (108, 109). Birse et al. found an increase in proteins 
involved in epithelial barrier remodelling and immune activation in the luteal phase, 
suggesting this represents a period of decreased barrier integrity and active immune cell 
recruitment to the mucosa, which might enhance HIV-susceptibility (45). An inflammatory 
profile has been suggested by gene expression analysis in the luteal (32, 127, 128) and late 
luteal (129) phase in vaginal (32), endocervical (127, 128) and endometrial (129) tissues. 
Such pro-inflammatory state in the FGT in the luteal phase could theoretically be associated 
with an increase in HIV-target cells in the luteal phase, which has been observed in some 
(126, 130), but not all studies (31, 32, 47, 131). A general increase in inflammatory 
cytokines in the luteal phase could potentially confirm an inflammatory state, but studies 
have shown inconsistent results, including both increase and decrease of individual 
inflammatory cytokines in the luteal phase, as well as no change (47, 50, 55, 132, 133). In 
addition, in a comprehensive study of mucosal markers of HIV susceptibility, Thurman et 
al. found no difference between the follicular and luteal phase (32), and the full impact of 
the menstrual cycle on HIV susceptibility in women remains to be elucidated. 
 
1.3.2.5 Progesterone and estradiol 
 
Estradiol and progesterone are steroid sex hormones that are synthesized from cholesterol, 
in the non-pregnant female the main production occurs in the ovaries. Prior to ovulation, 
such steroidogenesis occurs in the follicle, and after ovulation in the corpus luteum (134, 
135). Progesterone and estradiol can diffuse through the outer cell membrane and exert 
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their function by binding to intracellular ligand-activated steroid receptors, mainly the 
estrogen receptor (ER) and progesterone receptor (PR) for estradiol and progesterone, 
respectively. The hormone/receptor complex bind to the DNA strand at specific sites called 
hormone-responsive elements and thereby influencing gene transcription and protein 
synthesis (134). In addition to the genomic effects mediated by the nuclear receptors, 
progesterone and estradiol can bind to receptors on the cell-surface, which can induce 
direct, non-genomic effects (134, 135). There are subtypes/isoforms of the ER and PR and 
the expression of the different receptors varies throughout the FGT (135). However, the 
biological response is not only dependent on the type of receptors expressed but also on the 
tissue expression of intracellular proteins, such as coactivators or corepressors, that can 
modify the effect (134). Progesterone and estradiol can also modulate the effect of the 
other- in uterine cells, estradiol stimulates the expression of PRs, and progesterone can 
decrease the expression of ER (136). This highlights the complex interplay between 
estradiol and progesterone as well as the importance of the “priming” of the endometrium 
by estradiol during the follicular phase to prepare for progesterone-induced changes during 
the luteal phase. Progesterone can bind and exert its action by the PR, but it can also, to 
varying degrees, signal through other nuclear receptors (110). 
1.3.2.6 Hormonal contraceptives 
 
The development of HC has revolutionized women’s sexual freedom and the use of HC is 
now widespread worldwide. There are different formulations of HC such as per oral pill, 
injectable, intrauterine device, skin patch, vaginal ring and subdermal implant. Progestins 
are synthetic progestogenic steroids designed to act with progesterone-like effects to the 
PR, some HC contain only progestin whereas others contain progestin and a synthetic 
estrogen component. They are several different progestins used in HC and importantly, they 
exert their effect not only via the PR receptor but the different progestins show differential 
affinities and activities via other steroid receptors, such as glucocorticoid receptor (GR) and 
the mineralocorticoid and androgen receptors (reviewed in (110)). 
 
The most common type of HC in sub-Saharan Africa are long-lasting injectables, most 
often depot medroxyprogesterone acetate (DMPA). DMPA is a progestin-only HC that is 
provided intramuscularly every 12th weeks and prevents pregnancy by blocking the LH-
surge (resulting in anovulation) as well as thickening of the cervical mucus and endometrial 
thinning. However, meta analyses of high-quality observational studies have estimated that 
DMPA usage is associated with an up to 50% increased risk of HIV acquisition relative to 
no use of HC (22-24). Yet, it remains unknown if such increased risk is due to the 
biological effects of DMPA or because of limitations of the observational studies, such as 
confounding or bias. To reduce the limitations of observational studies, a large randomized, 
multicenter study compared DMPA with two other types of long-lasting contraceptives—
levonorgestrel implant and copper-intrauterine device (137). Here, DMPA usage was not 
found to be associated with an increased risk for HIV acquisition compared to these 
compounds, although critically, this study lacked a comparison between DMPA and no 
contraception or infrequent condom use. In addition, this study was designed to detect a 
“substantial” or “meaningful” increase in HIV risk between study arm, such risk defined as 
high as at least 50% difference. Thus, a clear epidemiological link between HIV infection 
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risk and DMPA use remains to be established (138). Interestingly, no increased HIV-
acquisition risk has been observed for NET-EN (22), another progestin-only injectable 
contraceptive, although data are somewhat limited. A proposed mechanism of the varying 
effects of DMPA and NET-EN on HIV-acquisition is via the GR, since the progestin 
medroxyprogesterone acetate (MPA) in DMPA but not NET (the progestin in NET-EN) 
show strong effect on the GR (139). 
 
Most studies show no association between combined oral contraceptives, i.e. contraceptives 
with both an estrogen and a progestin component, and HIV-susceptibility (22, 23). 
Moreover, in the non-human primate model, vaginal and systemic estrogen treatment is 
protective against vaginal SIV transmission (140, 141). In addition, in post-menopausal 
women, local estrogen treatment is associated with a thicker vaginal epithelium (131). The 
use of DMPA suppresses endogenous estradiol production and is associated with 
hypoestrogenism (142, 143). Taken together, this once again raises the suspicion whether 
high levels of progesterone and/or progestins is associated with increased HIV acquisition, 
and that perhaps estradiol exerts a protective effect on the female genital mucosa. 
 
One theory of how MPA and/or other progestins might contribute to increased HIV-
susceptibility is by causing a thinner vaginal/ectocervical epithelium. This has been clearly 
demonstrated in non-human primates (43, 144), but studies in humans are inconclusive and 
most studies do not show a substantial effect on epithelial thickness in response to 
exogenous progestins (31, 34, 143, 145). It has been hypothesized that MPA/progesterone 
increases HIV susceptibility by modulating the inflammatory/immune activating milieu in 
the FGT and recruitment of HIV target cells (31, 130, 146, 147). Some previous studies 
show an increase in genital inflammation (as measured by cervicovaginal cytokines) in 
response to DMPA treatment (50, 148) while others instead observe a general decrease 
(149, 150). The data on HIV-target cells is also rather contradictory, DMPA use has been 
associated with increased genital target cells in some (31, 130, 147) but not all (151) 
studies. 
1.3.3 The cervicovaginal microbiome 
 
The cervicovaginal microbiome is critical for maintaining vaginal health and mucosal 
barrier function. Recent advances in molecular technologies have allowed the identification 
of clusters, called “community state types” or “cervicotypes”, based on the composition of 
the cervicovaginal microbiome (152-156). Although heterogeneity exists between studies, 
all studies identify clusters dominated by different species of lactic-acid producing 
Lactobacillus as well as high diversity clusters usually dominated by Gardnerella and other 
facultative anaerobic or anaerobic bacteria. Such high diversity states, characterized by a 
loss of Lactobacillus with subsequent overgrowth of anaerobic bacteria, is often associated 
with the clinical diagnosis of bacterial vaginosis (BV) (155, 157). Additionally, high 
diversity states are more prevalent in women in sub-Saharan Africa than in Caucasian 
women from the developed world (19, 152, 153). In addition, black North American 
women show higher diversity and less Lactobacillus dominance as compared to Caucasian 
women from the same geographical area (152). The reasons for such ethnic differences in 
cericovaginal microbiome composition are not known but could be related to genetic 
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variations such as polymorphisms in genes associated with immune and hormone-response 
(158). 
 
Increasing bacterial diversity is associated with elevated genital inflammation (19, 52, 153, 
159) and increased risk of HIV-acquisition (19, 160) suggesting a link between 
cervicovaginal bacteria and the local immunological milieu in the FGT mucosa. Significant 
alterations in the cervicovaginal proteome, especially relating to epithelial barrier function, 
has also been observed with increasing diversity (52) and Gardnerella vaginalis-dominated 
communities (161). Also, cervicovaginal microbiome composition can alter the genital 
immune response to DMPA (162) and non-steroidal anti-inflammatory drugs (163). In 
addition, a recent study by Klatt et al. demonstrated that a cervicovaginal microbiome 
dominated by Gardnerella vaginalis and other anaerobs decreased the efficacy of a 
microbicide containing the antiviral agent tenofovir (164). This highlights the importance 
of considering the cervicovaginal microbiome in the HIV prevention field. Interestingly, 
cervicovaginal microbiome clusters dominated by the different species of Lactobacillus, 
mainly L.crispatus and L.iners, seem to have distinct effects of genital inflammation (52, 
153) and HIV-susceptibility (19), with L. crispatus dominated cervicovaginal microbiomes 
associated with the lowest risk of HIV-acquisition as compared to high-diverse states. 
Collectively, the above mentioned studies indicate that the cervicovaginal microbiome play 
an important role in genital inflammation and mucosal barrier function, which may have 
implications for HIV-susceptibility. 
 
The interplay between the vaginal microbiome, female sex hormones including HC, and 
genital inflammation is an area of great interest within the field. A systematic review 
suggested that DMPA is associated with a decrease in BV (i.e. an increase in Lactobacillus-
dominated microflora) (165), whereas other studies have shown either no change (130, 
153), or a decrease (142, 151) in the prevalence of Lactobacillus species in users of 
injectable progestin-contraceptives, mostly DMPA. However, the studies differed in study 
design (longitudinal vs. cross-sectional), as well as which methods were used to determine 
vaginal microbiota composition (culture based vs. 16S rRNA gene sequencing). In addition, 
Miller et al. (142) and Mitchell et al. (151) only observed a decreased in H202-producing 
Lactobacillus. Such results of decreased Lactobacillus in DMPA users are however 
supported by a recent study in Kenyan FSWs showing that MPA correlated with increased 
diversity of the cervicovaginal microbiome (166). Nevertheless, there remains a substantial 
lack of knowledge within the field about the effect of DMPA on the vaginal microbiome, 
and especially on underlying mechanisms. Few studies have examined the relationship of 
vaginal microbiota to the menstrual cycle in detail but observable changes have included 
decreased stability (167) and increase in Gardnerella vaginalis (168) or non-Lactobacillus 
(169) taxa during menstruation. Furthermore, while the functional properties of the 
microbiome are implicated in proper mucosal functioning and inflammation (reviewed in 





1.4 PROPOSED CORRELATES OF PROTECTION AGAINST HIV IN HIV-
EXPOSED SERONEGATIVE INDIVIDUALS 
 
Some individuals remain HIV seronegative, defined by lack of HIV Immunoglobulin (Ig) G 
in plasma or serum, despite continuous exposure to HIV, referred to as HIV-exposed 
seronegative (HESN) individuals in the scientific literature (171). However, there is no 
consensus of the amount of HIV-exposure needed to be classified as a HESN individual, 
and definitions vary widely between studies. Nevertheless, studying mucosal samples from 
HESN women can help elucidate natural protection to HIV and identify signatures 
associated with continuous HIV-exposure.  
 
The one confirmed resistance mechanism towards HIV is a homozygous, 32-base pair 
deletion in the gene coding for the HIV coreceptor CCR5 (172). However, this deletion is 
uncommon in black Sub-Saharan populations (173) and accounts for only very few cases of 
resistant individuals. This has led to the speculation that other factors contribute to 
decreased susceptibility to the virus in HESN individuals. Several proposed correlates of 
protection to HIV in HESN individuals have been identified (reviewed in (174-177). Earlier 
work focused on plasma/blood, but more recent studies have focused on the FGT mucosa. 
However, following many years of research in the field, it may be concluded that the 
mechanisms for a relative protective phenotype against HIV infection is most likely a 
combination of multiple factors. 
1.4.1 FSW cohort studies of mucosal protection against HIV 
 
Many studies investigating proposed mucosal correlates of protection to HIV have been 
performed in FSW cohorts (171). FSWs are often engaged in high-risk sexual behavior and 
have high levels of concordant STIs and are therefore at substantial risk of HIV infection. 
FSW cohorts can therefore be useful to study to decipher factors associated with HIV-
susceptibility (171). 
 
Several chemokines and cytokines have been identified as overexpressed in genital samples 
of HESN FSWs, such as RANTES/Chemokine (C-C motif) ligand (CCL) 5 (178, 179) and 
interferon-a (179). These cytokines have known anti-HIV activity in vitro; RANTES is 
secreted by CD8+ T cells and other cells, and inhibits HIV infection by competing with the 
virus binding to the CCR5 receptor (180, 181), and interferon-a can inhibit HIV-replication 
(182). However, the presence of RANTES is truly a double-edged sword since RANTES is 
also a potent chemoattractant for T-cells (72), that may function as HIV-target cells. In 
contrast to the above mentioned increase in cytokines, a decrease in cytokines has also been 
observed in genital secretions of HESN FSWs (183, 184). Other proteins that have been 
elevated in the FGT of HESN FSWs are several with anti-inflammatory properties such as 
serine protease inhibitors (57, 62, 63, 185) and cysteine protease inhibitors (62), known as 
serpins and cystatins, respectively. Such decrease in cytokines and upregulation of anti-
inflammatory proteins supports the hypothesis proposed by Card et al that HESN may be 
protected against HIV based on a phenotype of low baseline immune activation in the 
periphery and genital mucosa, called “immune quiescence” (174). The Immune quiescence 
theory was based primarily on low T-cell activation, including lower baseline cytokine 
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production in peripheral blood mononuclear cells (PBMCs) (186), and an increase in 
regulatory T-cells in the periphery of HESN individuals (174, 187). In the FGT, in addition 
to the increased levels of antiproteases and decreased cytokines mentioned above, cervical 
mononuclear cells show reduced gene-expression for the Th17 associated cytokines IL-22 
and IL-17 (188). This is especially interesting since Th17 cells have been implicated as 
especially susceptible to HIV-infection (79, 189), and a decreased presence or activation of 
these cells could indicate a protective phenotype. 
1.5 HIV-SERODISCORDANT COUPLES 
 
HIV-serodiscordant couples are couples with one HIV-seronegative and one HIV-
seropositive partner. HIV-serodiscordance is common in sub-Saharan Africa, and it is 
estimated that 44% of new HIV-infections in Kenya occur within stable relationships (190). 
The infectious burden of the HIV-seronegative partner varies greatly between cohorts and 
is dependent on many factors, such as type of sex, frequency of sexual intercourse, male 
circumcision, partner’s viral load and if the partner is taking ART. However, studies of 
HIV-serodiscordant couples can still aid our understanding of natural protection in high-
risk groups as well as the immune response involved in repeated HIV exposure. In addition, 
since HIV-serodiscordant couples are an important target group for preventative HIV 
measures, it is of importance to characterize their mucosal phenotype to correctly design 
and interpret clinical trials in this risk group. 
 
A small study in HIV-serodiscordant couples identified the innate molecules a-defensins 
human neutrophil peptide (HNP)1-3 to be overexpressed in genital tissues from HIV-
seronegative women in HIV-serodiscordant couples (191). However, the authors conclude 
that it cannot be determined if the a-defensins contribute to resistance to HIV in these 
women or if it is an effect of chronic immune stimulation. In contrast, Levinson et al. did 
not observe a difference in HNP1-3 in a cohort of Kenyan HIV-serodiscordant couples as 
compared to low-risk controls, but they did observe that high viral load of the HIV-positive 
partner correlated with higher levels of HNP1-3 (192). This could indicate that exposure to 
high viral load induced a local inflammatory response with release of HNP1-3. 
Interestingly, HNP1-3 were associated with increased HIV acquisition in a FSW cohort 
(61). However, increased levels of HNP1-3 were associated with bacterial STIs, and 
perhaps the genital inflammatory response to STIs with a potential increase in HIV target 
cells, overrode the antiviral activities of the a-defensins. 
 
In addition to molecules of the innate immune systems, studies indicate that components of 
the adaptive immune system might be altered in HIV-serodiscordant couples. Choi et al. 
demonstrated that HIV-1 neutralizing IgA antibodies were five times more common in 
genital secretions of women in HIV-serodiscordant relationships as compared to low-risk 
controls (193). However, in a smaller study, HIV specific IgA antibodies were not found in 
genital secretions of the HIV-seronegative partner (194) and the presence and effect of 
mucosal HIV-specific IgA antibodies in HESN individuals remains controversial (195). 
HIV-specific T-cell responses have been observed in PBMCs from the HIV-negative 
partner in serodiscordant couples (196, 197), but the T-cell response of genital lymphocytes 
in HIV-serodiscordant couples remain largely unknown. Thus, the genital mucosal 
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environment in HIV-serodiscordant couples remain largely unexplored, and it is essential to 
characterize this as these individuals represent an important target group for preventative 
HIV measures. 
1.6 HIV PREVENTION STRATEGIES 
 
Despite significant reduction in HIV-infection rates in many countries, there is still a great 
need for effective HIV-prevention strategies against HIV-transmission including ART, 
vaccines, microbicides, male circumcision and pre- and post-exposure prophylaxis (PrEP 
and PEP, respectively). Furthermore, women may not be able to negotiate condom usage, 
and it is therefore especially important to develop female controlled HIV-prevention 
strategies. 
1.6.1 Antiretroviral therapy 
 
One of the greatest scientific advances in the HIV field is the discovery and wide-spread 
use of ART. Standard ART consists of the combination of at least three antiretroviral drugs, 
and the WHO recommends ART initiation in all HIV-positive individuals regardless of 
CD4 T-cell count (198). ART not only reduces morbidity and mortality, but it can reduce 
viral loads to undetectable levels, and the Public Health Agency of Sweden concludes that 
there is no risk of transmission of HIV during sexual intercourse if the HIV positive partner 
fulfill the criteria for effective treatment with ART, including long-lasting viral suppression 
(199). Thus, widely accessible ART is a very important HIV prevention strategy and ART 
accessibility is one of the cornerstones of the UNAIDS strategies to combat the HIV 
epidemic. Despite recent advances in global ART coverage and viral suppression, only 53% 
of all people living with HIV were estimated to be virally suppressed in 2018 (8). In 
addition to ART in HIV-positive patients, PrEP are antiretroviral drugs that can be taken 
orally or administered locally as a microbicide (see section below) in HIV-seronegative 
persons with high risk of HIV-infection in order to decrease the risk of HIV-acquisition. 
1.6.2 Vaccines 
 
It has proven difficult to develop an effective preventative vaccine against HIV, partly 
because HIV is able to form latent proviral deoxyribonucleic acid (DNA) and targets for 
neutralizing antibodies are highly variable and camouflaged by heavy glycosylation (200). 
Most recently, a phase IIb/III follow-up trial to the moderately successful RV144 (201) was 
ended early because the regimen did not prevent HIV infections (202), being a significant 
setback for the vaccine field. However, there are other vaccine efficacy trials underway in 
sub-Saharan Africa as well trials testing passive antibody immunity (Bekker Lancet 2020), 
giving hope to finding an effective vaccine. 
1.6.3 Microbicides 
 
Microbicides are topical compounds that are inserted vaginally or rectally to prevent HIV-
transmission. There are different microbicide formulation, such as gels/creams, enemas, 
vaginal films or vaginal rings, and they contain medications that exert their action by either 
inhibiting HIV-entry into immune cells or preventing viral replication (203). As of today, 
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microbicides against HIV are only at the research stage, but there are some promising 
findings. In the CAPRISA 004 trial, a tenofovir-based gel inserted vaginally prior to and 
after coitus showed an overall reduction of 39% in South African women (204). 
Interestingly, genital inflammation (94) and Gardnerella-dominated vaginal microflora 
undermined efficacy of the gel (164). Such findings highlight the importance of the 
mucosal milieu in microbicide efficacy and indicate that reducing genital inflammation 
and/or modifying vaginal microbiota composition in women may augment HIV prevention 
efforts. However, a follow-up phase 3 trial (FACTS 001) did not demonstrate efficacy in 
reducing HIV-transmission, and the authors concluded that alternative “products that are 
less user dependent… or do not need high adherence are needed” (205). Indeed, one of the 
disadvantages with gels is that is it considered “messy”, which might decrease adherence. 
In contrast, vaginal rings are more user friendly, and a monthly vaginal ring system 
containing the antiretroviral dapivirine decreased HIV incidence by approximately 30% in 
two phase III trials (206, 207). Results from an open-label extension trial (DREAM trial) 
for the dapivirine ring indicate higher adherence as compared to the previously mentioned 
trials and a statistically simulated risk reduction rate of 63% (208). 
 
Important lessons for the field can be learned from the failure of the Nonoxynol-9 gel-
microbicide in FSWs, where frequent use increased HIV-acquisition (209). Subsequent 
studies showed that Nonoxynol-9 induce genital inflammation (210) and a thinned vaginal 
epithelium in a murine model (211). The Nonoxynol-9 study highlights the importance of 
rigorous pre-clinical safety studies of the genital mucosa and evaluation of markers of 







The overall aim of this thesis was to investigate factors associated with HIV susceptibility in 
the FGT. The specific aims were as follows: 
I. To study the effect of endogenous and exogenous female sex hormones on the mucosa 
in the FGT by assessing genital samples from: 
a. longitudinally followed Swedish healthy women over one menstrual cycle (Paper 1) 
b. HIV seronegative FSWs using injectable progestin-based HC (DMPA) vs. those 
who use no HC (Paper 4) 
II. To study the effect of seminal plasma on the immune response and HIV-transmission in 
the FGT using a human ectocervical explant model (Paper 2) 
III. To characterize the cervicovaginal protein signature in women living in HIV-
serodiscordant relationships (Paper 3) 
IV. To evaluate the feasibility of using a bead-based affinity set-up for high-throughput 





3 MATERIAL AND METHODS 
3.1 STUDY COHORTS AND SAMPLE COLLECTION 
 
All study participants for Paper 1-4 were over the age of 18 and answered questionnaires 
about medical history and sexual practices at enrollment. 
3.1.1 Paper 1: The Immunology of Menses (IMMENSE) cohort 
 
Healthy, Swedish volunteers were recruited and sampled at three time points during one 
menstrual cycle, aiming for day 7, 14 and 21 since initiation of last menses. Inclusion criteria 
included age 18-35, regularly cycling with menstrual cycle length of 24-35 days and no use of 
HC for the past 3 months. Exclusion criteria were frequent recurrent episodes of BV or 
vaginal candidiasis. Participants were instructed not to have unprotected sex 48 hours prior to 
sampling. All participants were tested, and excluded if positive, for the following at 
enrollment: HIV-1/2, Chlamydia trachomatis, Neisseria gonorrhoeae, cervical cellular 
dysplasia, and genital herpes simplex-like lesions. Participants were also screened for BV by 
clinical examination. Human papilloma virus (HPV) testing was also performed, but 
asymptomatic HPV was not exclusionary. At each visit, venous blood was collected for 
measurement of female sex hormones. CVS were collected by rotating one cotton tip in the 
cervical os, and another cotton tip was used for collecting secretions in the posterior fornix. 
Both cotton tips were transferred into the same vial containing 5 ml phosphate buffer solution 
(PBS), kept on ice and transported to the lab where it was centrifuged to remove cellular 
debris and subsequently stored at -80oC. The cellular debris is here referred to as the “cell 
pellet”, and was suspended in RNA-later before stored at -80oC until use. 
3.1.2 Paper 2: The St Göran hysterectomy cohort 
 
Pre-menopausal women undergoing hysterectomy for non-malignant and non-inflammatory 
causes at St Görans Hospital (Cevita Care GynStockholm St Göran), Stockholm were 
included in this study. Exclusion criteria included systemic immunosuppressive therapy, 
clinical symptom of an STI in the three months prior to surgery and/or HPV positivity. 
Immediately after the hysterectomy, 4-9cm2 sample of mucosa was dissected from the 
ectocervix by a pathologist, put in 4oC culture medium and kept on ice until processed. HPV 
genotyping of the cervix was performed on cervical swabs. After dissection of the 
ectocervical tissue into 8 mm3 tissue blocks, one tissue block was immediately snap-frozen 
and cryopreserved at -80oC, and the other tissue blocks were utilized for the fresh explant 
model. Semen was collected from HIV-negative adult volunteers recruited at the Venhälsan 
clinic of the Södersjukhuset. Exclusion criteria included clinical symptoms of STIs within 3 
months prior to donation, infertility (if known) and systemic immunosuppressive therapy. The 






3.1.3 Paper 3: Couples Against Transmission cohort 
 
The study participants included in this study were part of a larger cohort that has been 
described previously (212). Women in HIV-serodiscordant relationships, where the male 
partner was HIV-seropositive and the female partner was HIV-seronegative, were recruited at 
voluntary counseling and testing centers in Nairobi, Kenya between 2007 and 2009. This 
group is referred to as the “serodiscordant group”. HIV-seronegative women in 
seroconcordant couples (i.e. with a HIV-seronegative sexual partner) were recruited from the 
same testing centers and included as a control group. Eligible participants were not pregnant, 
reported sex ≥ 3 times with their study partner in the past three months and planned to remain 
together with their study partner for the duration of the study. Participants with a study partner 
currently on ART or with a history of clinical AIDS were excluded. The study participants 
were counselled about safe sex practices and had access to free STI testing and treatment. 
Women in serodiscordant couples reported high level of safe sex practices, and only18% 
reported unprotected sex in the past month. The HIV incidence for male-to-female in the 
larger parent study cohort is low at 1.1 per 100 person years (212). Questions on antiviral use 
were asked at study exit, and the use of PrEP and PEP in this cohort can be assumed to be 
low. 
 
The serodiscordant women were sampled with CVS (same procedure as in Paper 1) at 
enrollment (‘0’), 6 and 12 months later. Participants in the control group were only sampled 
once. All participants were tested for BV, Trichomonas vaginalis, syphilis, herpes simplex 
virus (HSV)-2 serostatus and HIV at enrollment. HIV and HSV-2 was tested at all visits 
included in this study and BV was assessed by Nugent Score. HIV RNA levels and CD4 cell 
counts were measured at every study visit for HIV-seropositive male partners. Prostate 
specific antigen (PSA), as a measure of recent unprotected sex (213), was measured in CVS at 
enrollment. For the part of this study where comparing the protein profile of serodiscordant vs 
control women (more details below), women using HC were excluded. In the partially 
overlapping cohort that was used to compare two proteomic techniques, women using HC 
were included. 
3.1.4 Paper 4: The Pumwani cohort 
 
The samples used in this study were part of a larger, longitudinal cohort within the Pumwani 
FSW cohort, this cohort has been described in detail previously (147, 214). Briefly, this 
community-based cohort of FSWs in the slum of Kibera, Nairobi, Kenya was established in 
1984 to study the epidemiology and immunobiology of STIs including HIV (215). Study 
participants and other inhabitants in the slum have access to basic health care, STI-testing and 
treatment as well as HIV-counseling at the study driven health centers. The women included 
in the study are self-defined FSWs, and there is no formal criteria that need to be fulfilled in 
order to be classified as a FSW. The mean number of clients per day in this cohort is 4 (216), 
and the majority of women also report regular sexual intercourse with at least one so called 
“regular partner”, such as boyfriend(s) or husband. The reported condom use is much lower 
with the regular partner than with clients. Data collected from the Pumwani cohort between 
 
20 
1985-1994 showed a high HIV incidence of 42 per 100 person-years (215). However, since 
then safe sex practices have increased substantially (147) and STIs decreased in this cohort, 
and the annual HIV-incidence rate was estimated to 2.2% between 2008 and 2011 (16). 
 
Inclusion criteria at enrollment included: actively involved in sex work, age 18-50, not 
pregnant/breastfeeding, no prior hysterectomy, not being menopausal, negative for Chlamydia 
trachomatis, Neisseria gonorrhoeae, HIV and syphilis. HIV- serology was performed at 
enrollment, approximately 6 weeks after the study visit and 3-6 months after study 
completion. For this sub-study, only HIV seronegative women were included. Study 
participants were either regularly cycling and not using any type of HC (control group) or 
using DMPA since at least 6 months (DMPA group). The regularly cycling controls were 
aimed at sampling in the follicular phase of the menstrual cycle based on self-reported days 
since last menses, and sampling in the DMPA group was aimed at 4-8 weeks since last 
DMPA injection. 
 
At the study visit, cervicovaginal lavage (CVL) was collected by washing the endocervix with 
2 ml sterile PBS, and the lavage was aspirated from the posterior fornix (217). Samples were 
kept on ice until processed in the lab, where they were centrifuged and aliquoted. The cellular 
debris (“cell pellet”) was resuspended in RNA-later, and the CVL and cell pellet were stored 
at -80oC until analysis. Two ectocervical biopsies were collected at the study visit, one was 
immediately snap frozen and the other placed in RNA-later. Both biopsies were stored at -
80oC until further analysis. The study participants were instructed not to have unprotected sex 
for 14 days post biopsy to enable healing, and they were compensated for loss of income 
during this time (214). To ensure healing and abstinence, the study participants were seen at 
the clinic 2-5 days post biopsy. 
3.2 ETHICAL CONSIDERATIONS 
 
Ethical permission from corresponding review boards were obtained for all studies presented 
in this thesis. 
 
Gynecological exams and the collection of genital samples can be associated with a feeling of 
discomfort. To minimize discomfort, all genital samples were collected by an experienced 
gynecologist. Ectocervical biopsies can cause light pain and bleeding, but are standard 
procedures that are part of routine screening for cellular atypia in Sweden and are generally 
well tolerated. 
 
The collection of ectocervical biopsies in a cohort of high HIV-risk women (Paper 4) may 
raise concerns of increased HIV susceptibility. To decrease the risk of HIV-acquisition post 
sampling, all women were asked to abstain from vaginal sex for two weeks. A rigorous study 
protocol was implemented to support post-biopsy abstinence, including counseling, text 
message reminders and PSA-testing 3-5 days post biopsy (214). The participants were also 
compensated for the loss of income during these weeks. The monetary compensation had 
been agreed upon together with representatives from the sex worker community and the local 
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ethics committee. In addition, ectocervical biopsies in high risk women have previously been 
considered safe and well tolerated (218). Study participants were tested for HIV 3-6 months 
after study completion, and none of the study participants seroconverted. 
 
None of the study participants received direct personal gain by being in the study, but we 
believe that the benefit of increased knowledge about HIV infection and prevention 
overweighed the discomfort of sampling. 
3.3 METHODOLOGICAL CONSIDERATIONS 
 
Described below are the most important methodological considerations, detailed descriptions 
of the methods used are presented in the corresponding papers or manuscript. 
3.3.1 Analysis of proteins in genital secretions 
 
The identification of proteins in genital secretions, defined here as both CVS and CVL, is 
commonly used to study mucosal immune responses in the FGT. Several techniques, used 
separately or in combination, that have been used to study proteins in genital secretions 
include enzyme-linked immunosorbent assay (ELISA), bead-based antibody techniques, 
Western blot and mass spectrometry (MS). Earlier research within the field has focused on a 
few individual proteins, but in the last decades, the field of proteomics has evolved. 
Proteomics is the large-scale study of proteins and is used to study the proteome, or all the 
proteins within a biological group, such as a cell, tissue or organ. Proteomics can be utilized 
to characterize genital secretions using a systems biology based-approach, which may provide 
a better understanding of the complex mucosal immune system since it allows examination of 
hundreds of proteins at the same time (219). Several proteomic techniques have been 
developed, of which quantitative MS and a high-throughput bead-based single-binder affinity 
assay will be discussed here because of their relevance to this thesis. 
 
It is important to keep in mind when interpreting results from protein profiling studies that it 
is a snapshot of a highly dynamic environment. In addition, the protein content of genital 
secretions tell us the amount (relative or absolute) of each protein, but not the biological 
activity, since it is dependent on the presence of other proteins, activation status of the 
proteins as well as localization in the tissue. Another issue is the lack of standardization for 
sampling of genital secretions, common sampling methods used include lavage (CVL), swabs, 
swabs diluted in PBS (CVS), cervical sponges, cervical cups and more. Not only does the 
different methods primarily sample different parts of the FGT, but protein yield varies 
between methods (220). 
 
3.3.1.1 Tandem mass spectrometry technique 
 






Figure 3. Schematic illustration of tandem mass-spectrometry. Proteins in CVS are digested by trypsin into 
peptides. These peptides are separated by liquid chromatography and injected one by one into the tandem 
mass spectrometer. The peptides are ionized using electrospray and separated by their mass to charge ratio 
(m/z) in the first mass spectrometer (MS1), resulting in a mass spectrum. Each peak/ionized peptide from 
the mass spectrum is then chosen for further fragmented into smaller peptide fragments in a collision cell, 
and analyzed again by a second mass spectrometer (MS2) in order to determine the amino acid sequence of 
the peptide. The data from the resulting mass spectrum is then compared against protein databases for 




MS proteomic techniques have been used extensively to study secretions in the FGT (219). 
An advantage of shotgun MS based techniques is that, in contrast to antibody based methods, 
no selection of proteins is needed prior to analysis, thereby allowing for a truly unbiased 
approach (Table 1). In addition, MS based techniques can identify different isoforms of 
proteins that might not be distinguished by antibody-based techniques because of similarity of 
amino acid sequences, such as the a-defensins HNP1-3 (221). Also, since it does not require 
antibodies directed towards the proteins of interest, MS-based techniques can also identify 











Tandem shotgun mass-spectrometry 
High-throughput bead-based single-




Not dependent on availability of high 
quality antibodies 
 
Can detect post-translational 
modifications and previously unknown 
protein isoforms 
Hundreds of samples can be analyzed at the 
same time 
 
Small amount of sample needed for analysis 
 
No depletion of high abundant proteins 
needed prior to analysis  
Limitations 
Time and labor intensive 
 
Extensive pre-sample treatment 
Dependent on the availability of high quality 
antibodies 
 
Antibody performance is context dependent 
and antibody validation needed for each 
sample type 
 
Table 1. Advantages and limitations of a tandem mass spectrometry based technique vs. a 
high-throughput bead-based single binder affinity assay. 
 
 
However, as with all methods, there are limitations. There is a large dynamic range of the 
proteome in genital secretions, and the presence of high abundant proteins can mask the 
detection of low abundant proteins. However, this can be compensated for by 
depletion/removal of high abundance proteins prior to analysis. Other limitations include 
extensive pre-sample treatment, the need for sophisticated software and that some MS 
techniques are labor and time intensive. 
3.3.1.2 Bead-based single-binder affinity assay 
 
In paper 3, CVS samples were analyzed using a high-throughput bead-based affinity assay 
(Figure 4). The antibody panel was designed using proteins selected based on previous MS 
analysis of genital secretions as well as proteins described as related to HIV resistance or 




Figure 4. Schematic overview of the bead-based set-up. A. CVS containing a plethora of proteins and 
antibodies. B. Samples are diluted and biotinylated. The black dots represent biotin attached to the proteins. 
C, D. In parallel to the steps described in A + B, antibodies selected for detection of proteins of biological 
relevance are immobilized to color-coded magnetic beads and mixed together to form a suspension bead 
array. E. The biotinylated samples are further diluted, heat treated and mixed with the suspension bead 
array. Unbound proteins are washed away after an overnight incubation and a streptavidin-conjugated 
fluorophore is added for detection. F. Read-out is performed using a FlexMap 3D instrument (Luminex 
Corp., Austin, United States), and binding events are displayed as MFI. CVS: cervicovaginal secretions. 
MFI: median fluorescence intensity. Adapted and reprinted with permission (222). 
 
High-throughput antibody based microarray techniques have emerged as a complement to MS 
based techniques (223). A large portion of the work can be automated and performed in 
microarray plates, thereby allowing many samples to be processed at the same time (224). 
One important aspect to achieve such high throughput is that the same amount of sample, 
regardless of initial protein content, is used for analysis. Another advantage is that no 
depletion of high abundant proteins is needed prior to analysis. 
 
A limitation is that proteins of interest need to be identified prior to analysis, and the method 
is thereby more suitable for hypothesis validating studies. The assay is also dependent on the 
availability of high-quality antibodies directed to the proteins of interest. The antibodies used 
in Paper 3 are generated via the Human Protein Atlas (HPA) project, a Swedish-based project 
aimed at mapping and producing antibodies against all human proteins (225). The HPA 
antibodies used in this thesis are created by immunizing rabbits with antigen, and the 
produced polyclonal antibodies are validated on protein microarray plates, but not in solution 
(226, 227). We can therefore not be certain of antibody specificity in complex environments 
such as genital secretions. One of the major challenges to antibody-based techniques such as 
this one is evaluating antibody selectivity- are we detecting the protein that we intend to? 
(228) However, there are several ways to evaluate antibody selectivity, such as sandwich 
assays and including several antibodies targeting different parts of the same protein. 
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Concordant results between these antibodies would support that the intended target was 
captured. 
3.3.1.3 Cytokine bead array immunoassay 
 
The concentration of selected cytokines in CVS (Paper 1) and explant conditioned medium 
(Paper 2) were measured using a multiplex bead array immunoassay. The cytokines chosen 
for study in both of these studies were pre-selected based on their function as inflammation 
regulators and abundance in genital secretions (50, 51, 133, 229, 230). The multiplex bead 
array immunoassay is well established and commonly used in immunological studies to 
identify and quantify the levels of cytokines/proteins. Using this bead-based technique, 
several cytokines can be measured simultaneously. A standard curve is used allowing absolute 
quantification of cytokines concentrations, in contrast to the other methods mentioned above. 
However, as for all antibody-based techniques, it is dependent on the availability of high 
quality antibodies. It is also more time and labor consuming than the high-throughput bead-
based affinity assay described above. 
 
3.3.2 Tissue based techniques 
3.3.2.1 In situ based imaging analysis 
 
In Paper 3, ectocervical and vaginal tissues were stained by immunohistochemistry for the 
visualization of six proteins of interest, the proteins were selected based on their association 
with the HIV-serodiscordant phenotype in the antibody-based affinity array analysis. In Paper 
4, ectocervical biopsies were stained by immunofluorescence for the immune cell marker 
CD4 and the adherence junction protein E-cadherin. 
 
The greatest advantage of in situ based imaging of genital tissues is the ability to visualize 
proteins and cells in intact tissue, thereby allowing assessment of their ‘natural’ abundance 
and distribution. A limitation is a dependency on high-quality antibodies and cross reactivity 
between antibodies limits the numbers of markers that can be assessed at the same time. 
Another limitation is that it is time and labor intensive and that it usually only allows semi-
quantitative analysis of cells/structures, making it difficult to compare results between studies. 
However, computerized image analysis allowing higher throughput and reproducibility have 
expanded over the years. A newly developed, quantitative image analysis workflow set up in 
our lab was used in Paper 4 to enumerate CD4+ cells and E-cadherin (see Paper 4 for details). 
3.3.2.2 Transcriptomics 
 
In Paper 4, the ectocervical biopsies in RNA-later were analyzed by RNA sequencing (RNA-
seq). All RNA molecules in a cell, population of cells, or tissue is referred to as the 
“transcriptome”, and transcriptomics is the study of the transcriptome. In contrast to the 
genome that is very stable, the transcriptome varies with external environmental conditions 




There are several important advantages of using transcriptomics to study tissues in the FGT. 
First of all, this unbiased approach can identity factors that might not have been uncovered 
using a hypothesis driven approach. Also, by focusing on pathways and group of genes rather 
than individual genes/proteins, it is possible to get a more comprehensive understanding of 
underlying biological mechanisms. To analyze the expression of only a few genes (i.e. not the 
entire transcriptome), reverse transcriptase based quantitative real-time polymerase chain 
reaction is the gold standard and widely used in research and clinical settings. For 
transcriptome profiling, there are two main methods used today: microarray and RNA-seq 
(231). RNA-seq have several advantages over microarrays, such as ability to detect wider 
dynamic range, higher specificity, less amount of RNA required for analysis and that is does 
not require transcript specific probes (231-233). However, a major challenge with RNA-seq is 
the amount and complexity of data generated, and that it does not yet exist a gold standard for 
analysis of this type of data. Another limitation when performing RNA-seq on entire tissues, 
as in our study, is that we do not know from which cells the transcripts originate, this however 
would be possible with single-cell RNA-seq. 
 
In the biological field, we are obviously interested in biological processes and the 
mechanisms that govern these. In cells, this is represented by proteins and the derivatives 
thereof. Gene expression is a proxy for protein expression, but the transcriptome is not 
directly corresponding to the proteome because of varying degrees of mRNA and protein 
degradation (234) as well as other post-transcriptional and post-translational events. On the 
other hand, detection of proteins also has limitations as they can easily be degraded and/or 
post-translationally modified. Therefore, the gene expression could be more representative of 
the activation state of the cell. Another advantage of transcriptomics is that nucleic acids such 
as RNA, in contrast to proteins, can be amplified which facilitates detection. 
3.3.2.3 The ectocervical tissue explant model 
 
The ectocervical explant model offers several key advantages for studying the mucosal 
immune response and mechanisms of HIV-transmission (235). For ethical reasons, the 
mechanisms of HIV-transmission in the female genital mucosa cannot be studied in vivo in 
humans, and the non-human primate field is restricted by anatomical differences in the genital 
tract between the species (235, 236). Cell lines, isolated primary cells and PBMCs are useful 
in studying many aspects of HIV, but because of lack of tissue architecture and the native 
communication between cells, these models do not accurately mimic mucosal events. Human 
cervical explant models can therefore serve as a bridge between cell culture models and in 
vivo studies. 
 
Among other key features of explant-based models of HIV infection, conserved tissue 
architecture, including the physiological spatial and functional relationship between multiple 
cell types, allow for a faithful representation of mucosal events, although for a restricted time 
window. Another important advantage is that explants can support HIV replication without 
exogenous stimulation as opposed to PBMCs (235, 237). In addition, it is a very versatile 
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model that can be used for microbicide testing (238). Explants can also be studied together 
with genital co-pathogens that are important for HIV-transmission (235). 
 
However, there are certain caveats and challenges associated with using human cervical tissue 
explants for HIV transmission research (239). A limitation of the explant system is that the 
tissues are disconnected from the body and blood supply, including immune cells, and it 
therefore does not fully mimic an in vivo system. Other challenges include donor-to-donor 
variability between explants, problems with reliable tissue polarization and progressive decay 
of tissue structure with culture time (235, 238). As compared to using cell lines, tissue 
explants are often more challenging to acquire which, together with high protocol complexity, 
make it a low-throughput method (238). Most tissues used for research originate from 
anonymous donors, and there is often limited clinical data available on tissue donors, 
including pre-surgical medications and hormone therapy. However, in our study 2, all study 
participants answered a questionnaire about medical history and exogenous hormone usage, 
and therefore this is not an issue in our study. 
3.3.3 Menstrual cycle phasing 
 
One of the reasons for the discrepancies in studies of the menstrual cycle might be the wide 
variety of ways of determining menstrual cycle phase in the scientific literature. The gold 
standard is the use of serial vaginal ultrasounds to determine when ovulation occurs (240), 
thereby identifying the follicular and luteal phase as prior to and after ovulation, respectively. 
However, this method is invasive, expensive and time consuming, and not feasible for most 
studies. Therefore, several other strategies to predict ovulation and/or menstrual cycle phase 
are used, alone or in combination, such as i) days since the first day of the last menstrual 
period (LMP) (45), ii) luteal phase serum/urinary progesterone cutoff (32, 241), ii) ratio of 
urinary estrogen and progesterone metabolites (242, 243), iii) ratio of serum progesterone >2 
in the luteal/follicular phase (47), iii) endometrial histology/dating (116), iv) identification of 
urinary/serum LH surge (124) and v) shifts in basal body temperature (244). Since the LH 
surge accurately predicts ovulation (240, 245), one of the best indirect method of estimating 
ovulation is serial sampling of LH in serum or urine (246). Prospective days since LMPs, 
counting days since last menses, is easy, inexpensive and non-invasive, yet considering the 
large variation in length of the follicular and luteal phase, this method cannot reliably identify 
menstrual cycle phase (119, 123). 
 
In order to as correctly as possible define the different phases of the menstrual cycle in Paper 
1, we used a combination of days since LMP and female sex hormones. The serum levels of 
progesterone, estradiol, LH and FSH were measured at every visit. For Paper 2, the majority 
of study participants had irregular bleeding patterns because of myomas and in some cases 
treatment with progestin-based compounds, and therefore menstrual cycle phase was not 
estimated. For Paper 3, no data on menstrual cycle phase was available. For Paper 4, the 
sampling was aimed for the follicular phase of the menstrual cycle based on LMP.  
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3.4 STATISTICAL ANALYSIS 
3.4.1 Paper 1 
 
To determine the effect of menstrual cycle phase on relative protein abundance (assessed by 
MS) and absolute cytokine abundance (in pg/ml, assessed by cytokine bead array 
immunoassay), we used a random intercept linear mixed effect (LME) model. The LME 
model was chosen primarily for its ability to handle missing data points as well as possibility 
to combine fixed and random effects. Fixed effects in the model were menstrual cycle phase 
and cervicovaginal microbiome composition (as defined by 16S rRNA gene sequencing) with 
an interaction term between fixed effects. Each woman (subject) was included as a random 
effect. Correlation analysis between serum hormone levels and protein/cytokine levels were 
performed using Spearman’s correlation. To adjust for multiple comparisons testing, 
Benjamini-Hochberg (BH) (247) adjustments were performed. Proteins with BH adj p <0.05 
and Log2 fold change >1 between menstrual cycle phases were considered significant. 
3.4.2 Paper 2 
 
In order to account for inter-individual differences between tissue donors and seminal-plasma 
pools, the results of the treated explants were normalized to donor-matched untreated 
explants, and this ratio was termed n-fold. The difference in n-fold change between culture 
conditions were compared against 1 using the Wilcoxon signed rank test. When groups of 
mixed paired/non-paired data were evaluated, n-fold differences were evaluated using the 
Mann-Whitney U. For groups containing only paired data, the Wilcoxon matched-pairs signed 
rank test was used to evaluate difference in n-fold. When the difference in n-fold change of 
cytokines between multiple groups were compared, Kruskal-Wallis test was used for groups 
with mixed paired and unpaired data, and the Friedman test for only paired data. Dunn’s post 
hoc test was applied, p <0.05 indicated statistical significance. 
3.4.3 Paper 3 
 
To assess differences in demographic parameters between the serodicordant and the control 
group, a logistic regression model was used. All p values were subjected to multiple 
comparisons testing using BH, and BH adj. p <0.05 were considered significant. 
3.4.3.1 Univariate analysis 
 
The relative abundance protein data from the affinity set-up were compared between the 
serodiscordant group and the control group using the Mann-Whitney U test because of non-
normality of the data. Two-group comparisons were evaluated between the control group and 
all three time points for the serodiscordant group, the presented numbers are the least 




3.4.3.2 Adjustment for potential confounders 
 
To adjust for potential confounders, we used two statistical models: a bivariate linear 
regression model and a LME model. Potential confounders were demographic parameters that 
varied (p<0.1) between study groups. The bivariate linear regression model was assessed for 
the proteins with BH adj. p<0.05. The log-transformed intensity of each protein was included 
as the dependent variable, and potential confounders including serodiscordant/control 
variables as independent variables. The bivariate linear regression models (one for each 
potential confounder) was compared to the crude model, and confounding was present if the 
adjusted model differed by greater than +/- 10%. In order to further evaluate the effect of 
potential confounders, the data was adjusted using a LME model. The above mentioned 
potential confounders were included as fixed effects, and visit code as an estimate of sample 
time was included as a random effect. This LME-adjusted data was subjected to univariate 
analysis (as described above) as well as a multivariate, discriminant data analysis approach. 
For this, a least absolute shrinkage and selection operator algorithm was applied to determine 
the minimum set of proteins necessary to distinguish the two study groups. 
3.4.3.3 Comparative analysis between MS and antibody-based data 
 
In order to validate the findings using a separate proteomic technique, a subset of samples 
were analyzed both by MS and the bead-based affinity technique. Median fluorescence 
intensity (MFI) values from the bead-based affinity technique were compared with abundance 
data from the MS analysis using Spearman’s correlation. 
 
3.4.4 Paper 4 
 
For the demographic parameters, Mann-Whitney U was performed to assess continuous 
variables and Pearson’s Chi-squared test was used to assess categorical variables between the 
DMPA and the control group. For the RNA-seq data, differences in gene expression between 
study groups (DMPA vs controls) were evaluated using linear regression and subjected to 
multiple comparison testing using false discovery rate (FDR). Differentially expressed genes 
were defined as FDR adj. p <0.05. For the imaging data, a Mann-Whitney U test followed by 
BH correction was used for comparisons between groups for the (in total) 18 measurements 





4 RESULTS AND DISCUSSION 
4.1 FEMALE SEX HORMONES AND HIV SUSCEPTIBILITY 
 
There is a plethora of evidence suggesting that female sex hormones, both endogenous and 
exogenous, influence HIV-susceptibility in the FGT. Some of the most important factors 
affected by female sex hormones include genital inflammation, epithelial barrier integrity and 
cervicovaginal microbiome composition, as discussed below. 
4.1.1 Endogenous female sex hormones 
 
In paper 1, our aim was to characterize how the fluctuations in female sex hormones over the 
menstrual cycle influence the local immunological milieu and cervicovaginal microbiome in 
the FGT. We also aimed to collectively evaluate the immunological and microbial changes 
associated with the menstrual cycle to reveal potential interactions. 
4.1.1.1 Proteins and cytokines in genital secretions 
 
In order to characterize the local immunological milieu, CVS were analyzed by MS and 
selected cytokines analyzed using a multiplex bead array immunoassay. Samples were 
classified as either follicular (n=13), ovulatory (n=5) or luteal (n= 14) based on the stringent 
criteria using days since LMP and serum hormone measurements. MS analysis revealed 406 
unique proteins in the cervical secretions. Using a LME model to adjust for cervicovaginal 
microbiome composition and baseline difference between women, the largest change in 
proteins composition was seen for the ovulatory phase as compared to both the follicular and 
luteal phases. The difference between the follicular and luteal phase was much smaller, and 
there was a large overlap in protein composition between these phases. 
 
In order to comprehensively characterize the biological pathways of the different phases, 
proteins including cytokine expression profiles were used for pathway analysis. In the 
follicular and luteal phases as compared to the ovulatory phase, pathways relating to immune 
response and cellular inflammation were predicted to be upregulated. There was a large 
overlap in pathways upregulated in these two phases, but the magnitude was in general larger 
for the luteal vs. ovulatory phase than for the follicular vs. ovulatory phase. Several proteins 
common for these pathways include neutrophil proteases, integrins, S100 proteins, 
antiproteases and leukocyte factors. In the ovulatory phase, pathways predicted to be 
upregulated included epithelial cell differentiation, tissue homeostasis and cell-to-cell 
adhesion. Inflammatory pathways, including leukocyte recruitment, were downregulated in 
the ovulatory phase. Proteins associated with the ovulatory phase included antiproteases 
important for regulating inflammation, mucins and proteins involved in epithelial barrier 
integrity and repair. Despite the high estradiol levels in the ovulatory phase, only one protein 
(KRT6C) was positively correlated with estradiol concentrations. To further characterize the 
inflammatory status of the different phases, we used a multiplex bead array immunoassay to 
measure selected cytokines. Several of these cytokines are present at low concentrations in 
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genital secretions and might not be identified by MS. The cytokine analysis revealed that 
three pro-inflammatory cytokines, namely TNF, CCL20 and interleukin(IL) 6, were reduced 
in the ovulatory phase as compared to the luteal phase (p<0.05), although none passed 
multiple comparison corrections. 
 
To conclude, the progesterone-high luteal phase was characterized by leukocyte and 
neutrophil recruitment pathways and pro-inflammatory cytokines. In contrast, the 
progesterone low, estradiol-high ovulatory phase was characterized by upregulation of anti-
inflammatory, wound-healing and antimicrobial pathways, as well as by a decrease in pro-
inflammatory cytokines. The follicular phase was a mixture between the other two, with 
inflammatory pathways upregulated, but to a lesser extent than in the luteal phase, and with 




Figure 5. Illustration of proposed mechanisms during the phases of the menstrual cycle. Figure originally 
published in (248), reprinted with permission. 
 
Several other studies have also reported an inflammatory profile in the FGT in the luteal 
phase (32, 45, 127, 128). Such pro-inflammatory state in the FGT in the luteal phase could be 
associated with an increase in HIV-target cells, which has been observed in some (126, 130), 
but not all studies (31, 32, 47, 131). Furthermore, a general increase in inflammatory 
cytokines in the luteal phase could potentially confirm an inflammatory state. We observed a 
slight increase in the inflammatory cytokines IL6, TNF and CCL20 in the luteal phase, but 
these results should be interpreted cautiously because they do not pass multiple comparison 
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testing. Previous studies of cytokine expression in genital secretions have shown inconsistent 
results, including both increase and decrease of individual inflammatory cytokines in the 
luteal phase, as well as no change (47, 50, 55, 132, 133). Other proteins with implications for 
decreased HIV-susceptibility, such as antiproteases including serpins, have been associated 
with the follicular phase (45, 46). In concordance with this data, we observed an increase in 
antiproteases in the follicular phase, but also in the ovulatory phase. We also showed a 
distinct increase in the antiprotease SLPI, with known anti-HIV-activity, in the ovulatory 
phase, whereas previous studies have shown a decrease (55), an increase (249) or no change 
(48, 53) in the ovulatory/midcycle phase. 
 
These inconsistent results warrant some discussion. Firstly, it should be noted that an 
inflammatory response will be followed by a counteractive anti-inflammatory response in the 
body, and this process is a continuum. Therefore, at a given timepoint, there will be both 
“inflammatory” and “anti-inflammatory” processes ongoing, and inflammation mediators 
from both such processes will be present at the same time. In addition, since the immune 
system is very complex and the function of each protein/cytokine is dependent on other 
proteins, it is precarious and can be misleading to focus on individual proteins/cytokines. 
Instead, the data must be interpreted collectively, such as by pathway analysis, to give a 
representative picture of the inflammatory state of the mucosa. 
 
In addition, there are several other possible explanations for the discrepancies between 
studies. Other factors likely to affect the results include the varying model systems and 
methods used, there is a the wide variety of methods used to estimate menstrual cycle phase 
as well as cross-sectional vs longitudinal study designs. We observed the largest difference in 
the short ovulatory phase, whereas many studies are lacking data on this phase. Also, there is 
a large variation in sex hormone levels within each menstrual cycle phase, and timing of 
sampling within each phase might vary between studies. A limitation of our own study is that 
we only assessed serum hormone measurements once a week, which could have contributed 
to a lack of detection of important hormonal fluctuations essential for menstrual cycle 
classification, such as the LH-peak. The progesterone cut-off level used to defined the luteal 
phase (ratio >2 as compared to the follicular phase) in our study is comparable to the cutoff 
used by others (47, 130). However, higher progesterone reference values levels are used in the 
clinical setting to define the mid-luteal phase, and our more lenient definition may affect 
protein expression.  
 
Although discrepancies between studies exists, the combined results of the above mentioned 
studies indicate that the luteal phase is associated with increased inflammation. Such 
increased inflammation and increase in HIV target cells could potentially explain an increase 
in HIV-susceptibility in the luteal phase (106, 113) that is observed in some, but not all (32, 
126) human genital explant studies, as well as non-human primate models (105, 106). It is 
also possible that the reduced mucosal levels of antimicrobials proteins, such as SLPI, 
observed in the luteal phase may facilitate HIV-transmission. In addition, proteins involved in 
epithelial barrier remodeling and tissue homeostasis were decreased, indicating that the 
epithelial barrier is weakened during this phase. As mentioned above, the largest change of 
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the luteal phase was in comparison to the ovulatory phase, which was associated with an 
increase in epithelial barrier proteins and decreased inflammation.  
 
Combined, an inflammatory profile, which could be associated with increased target cells, a 
decrease in antimicrobial proteins and a weakened epithelial barrier in the luteal phase may be 
associated with an increased HIV-susceptibility. In contrast, the ovulatory phase profile of 
decreased inflammation and target cells, an increase in antimicrobial proteins and a robust 
epithelial barrier may confer protection against HIV infection. 
4.1.1.2 The cervicovaginal microbiome and the menstrual cycle 
 
Although it is well established that the cervicovaginal microbiome influences the 
immunological milieu including epithelial barrier integrity in the FGT (19, 52, 153, 161), less 
is known about the interplay between the menstrual cycle, the cervicovaginal microbiome and 
the immune system. We wanted to characterize how the cervicovaginal microbiome fluctuates 
over the menstrual cycle as well as any potential interactions between the menstrual cycle and 
the cervicovaginal microbiome. 
 
To characterize the cervicovaginal microbiome , the V3-V4 region of 16S rRNA gene was 
sequenced, and Lactobacillus-dominance was defined as >50% of reads belonging to the 
Lactobacillus genus. The majority of study participants showed a stable microbiome 
composition over all visits: 63% (n=10) were consistently Lactobacillus-dominant, 25% (n=4) 
consistently non-Lactobacillus dominant and 13% (n=2) transitioned from one state to the 
other over the menstrual cycle. The 16S rRNA gene sequencing data was compared to data at 
the metaproteome level, and sample classification was concordant in 91% (43/47) of samples. 
Our findings of Lactobacillus-dominance are similar to other studies in Caucasian women 
(152, 154, 156). In concordance with several other (156, 167), but not all (250) studies, we 
observed a relatively stable microbiome composition across the menstrual cycle. Previous 
studies have observed an increased diversity (167), increase in Gardnerella (168) and/or other 
non-Lactobacillus taxa (169) around menses, but we did not assess menses-related changes in 
our study. 
 
To further characterize potential interactions between the menstrual cycle and the 
cervicovaginal microbiome, an interaction term between the two fixed effects (menstrual 
cycle phase and cervicovaginal microbiome composition) was added to the LME model. 
Several proteins important for the epithelial barrier demonstrated an interaction between these 
two effect. These proteins showed a significant decrease from the ovulatory to the luteal 
phase, but non-Lactobacillus-dominant women showed a greater decline in expression 
relative to Lactobacillus-dominant women. Of these proteins, the epithelial protein RPTN was 
the most significant and the only protein that passed multiple comparison corrections. Such 
findings could indicate that menstrual-cycle induced changes to HIV-susceptibility in the 
luteal phase could be reduced by Lactobacillus. However, because of the small sample size 
and only one non- Lactobacillus dominant woman in the ovulatory phase, these findings 
should be interpreted cautiously. In addition to the limitation of the small sample size 
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mentioned above, another limitation is that the 16S rRNA gene sequencing method used 
could not consistently distinguish between different species of Lactobacillus, and therefore no 
sub-analysis for different species of Lactobacillus was performed. In addition, it would have 
been very interesting to assess the effect of the cervicovaginal microbiome within each 
menstrual cycle phase, however, the study was not powered for this. To conclude, our results 
indicate that the cervicovaginal microbiome might influence cycle-related changes to 
epithelial barrier integrity. 
4.1.2  Exogenous female sex hormones 
 
Observational studies in sub-Saharan Africa suggest that the use of the injectable progestin-
containing contraceptives DMPA is associated with an up to 50% increased risk of HIV 
acquisition (22-24), although the results may be confounded by behavioral factors. Thus, as 
suggested, an epidemiological link remains to be established as defined by prospective studies 
comparing use of DMPA to relevant control groups (138). Suggested mechanisms for 
increased HIV-risk in women using DMPA in the FGT include an altered genital immune 
environment, including increased number and infectivity of HIV-target cells, and decreased 
epithelial barrier integrity, as discussed below. In Paper 4, our aim was to characterize how 
DMPA affects the ectocervical epithelium using RNA-seq and in situ based imaging. 
 
RNA-seq was performed on ectocervical tissue from Kenyan FSW using DMPA (n= 32) and 
control women without HC usage (n= 65), aimed at collection in the follicular phase of the 
menstrual cycle. The DMPA group was significantly younger and reported shorter duration of 
sex work, but comparable for the remaining demographic parameters. Of the 15,326 identified 
genes, 1,279 (8%) and 1,244 (8%) were upregulated (FDR p <0.05) in the DMPA and the 
control group, respectively. Of these top upregulated genes in the DMPA group, several 
(OLFM4, PCDH8, DUSP4) are regulated by estrogens (251-253). We also observed an 
increase in the gene coding for the neutrophil-attracting chemokine CXC motif chemokine 
(CXCL)6 (254). In the DMPA group, genes associated with epithelial barrier structure and 
function were downregulated (Figure 6). Interestingly, desmosomal cadherins were also 
downregulated in the DMPA group, and the protease CAPN14, that degrades the desmosomal 
cadherin DSG1 (255), was upregulated. 
 
To further characterize the effect of DMPA on the epithelium, the differentially expressed 
genes were used to identify gene sets and biological processes using a gene ontology software. 
The most upregulated and downregulated biological processes in the DMPA group were 
related to immune activation and development and maintenance of the epithelium, 
respectively. These results are concordant with the results of the individual gene analysis, 
indicating that both epithelial barrier genes and pathways were downregulated in the DMPA 
group. In contrast, genes and biological pathways related to immune activation were 




Figure 6. Schematic illustration of the proposed effects of DMPA use on the ectocervical epithelium. Created 
using Biorender.com.  
 
To complement the gene expression analysis at the structural and protein level, the 
ectocervical tissue biopsies were evaluated by in situ staining combined with digital tissue 
analysis to measure epithelial thickness, evaluate integrity and assess HIV-target cell numbers 
and localization. Our results show that the DMPA group have thinner superficial layer as 
compared to the control group, but there was no difference in total thickness of the 
epithelium. The DMPA group also had a lower E-cadherin coverage in the epithelium and a 
higher proportion of CD4+ cells located in the upper intermediate layer (the layer just below the 
most superficial layer). 
 
Previous studies indicate that desmosomal cadherins are affected by DMPA use (35, 256, 
257) and a downregulation of desmosomal cadherins was observed in our gene expression 
analysis. We therefore wanted to look specifically at the expression of the desmosomal 
cadherin Desmoglein-1 in tissues, and immunofluorescent in situ staining of Desmoglein-1 
was performed on three representative samples from each study group. Visual inspection in 
this limited sample set revealed that Desmoglein-1 was mostly present in the lower 
intermediate layer, and that the area coverage of Desmoglein-1 was lower in the DMPA group 
as compared to the control group. 
 
To summarize, in Paper 4 we demonstrated that the use of DMPA is associated with an 
increase in immune activation pathways. We also observed a downregulation of genes coding 
for epithelial barrier proteins and pathways involved in epithelial barrier development and 
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differentiation in the DMPA group. Desmosomal genes were downregulated, which was also 
visualized at the protein level using in situ based imaging. Confirming the results of a weaker 
epithelial barrier obtained by gene expression analysis, we observed a thinner superficial layer 
and a more leaky epithelium, as assessed by E-cadherin expression, in women using DMPA. 
 
Our results indicate an enhanced immune activation in the FGT. Previous studies from in vivo 
studies on the effect of DMPA on soluble immune modulators in the FGT, such as cytokines, 
are however contradictory - studies show a general increase (50, 148), decrease (149, 150) or 
selective but not broad increase (258) in inflammatory cytokines. There are several plausible 
explanations for such discrepancies between studies, including differences in study design 
(size of study population, cross-sectional vs longitudinal, time span between measurements) 
as well as population differences in cervicovaginal microbiome composition and/or STIs and 
variability in expression of factors depending on site of sampling within the FGT. Indeed, a 
microarray based transcriptomics study observed a pro-inflammatory profile in DMPA-users 
in endometrial tissues, but not in tissues from the transformation zone (259). This is in 
contrast to our study, where we observed such signature of immune activation in the 
ectocervix. Our results are also in contrast with those of Zalenskaya et al., that observed a 
downregulation of genes involved in immune activation in DMPA users in ectocervical 
tissues (35). However, in a subgroup of DMPA-users in their study, molecular functions 
associated with immune cell movement categories were activated, indicating that DMPA may 
have varying effect in different individuals/subpopulations. Immune activation can also be 
evaluated by numbers of HIV-target cells in the FGT, and DMPA has been associated with 
increased target cells in some (31, 130, 147) but not all (151) studies. Although we did not 
find an increase in total CD4+ cells, used as a proxy for HIV-target cells, in DMPA users, we 
did observe a more apical distribution, suggesting that the CD4+ cells are more accessible to 
virus particles at the vaginal lumen. 
 
DMPA is associated with a dramatic thinning of the cervicovaginal epithelium in non-human 
primates (144), but the majority of studies in humans do not demonstrate a significant effect 
(31, 34, 143, 145). However, these studies evaluate total epithelial thickness, whereas our 
imaging technique allowed specific measurements of the layers within the epithelium. In 
concordance to the above mentioned studies, we did not observe a difference in total epithelial 
thickness in DMPA users, but, as stated above, we noted a thinner superficial layer. A thinner 
superficial layer in response to DMPA was also demonstrated in non-human primates (260) as 
well as in progestin-containing intrauterine device users (33). In the latter study, the progestin 
intrauterine device was also associated with a decrease in the expression of the tight junction 
protein ZO-1, indicating a weakened epithelial barrier. Although we did not specifically 
assess ZO-1 by in situ staining, we observed lower coverage of the adherence junction protein 
E-cadherin coverage in the DMPA group. This, in combination with a thinner superficial 
layer, indicate a weaker epithelial barrier and easier access for the virus to HIV target cells.  
 
In additional to potential effects of DMPA on ZO-1 (expressed in epithelial tight junctions) 
and E-cadherin (expressed in adherence junctions), recent studies indicate a DMPA-induced 
effect on desmosomes in mice (256, 257) and humans (35, 256). Desmosomes contribute to 
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cell-cell adhesion between keratinocytes in epithelia and, together with tight junctions and 
adherence junctions, strengthen epithelial integrity (37). We observed a downregulation of the 
desmosomal proteins at the gene level in DMPA users, and protein expression of the 
desmosomal protein Desmoglein-1 was confirmed by in situ based imaging. In addition, the 
protease CAPN14, that degrades Desmoglein-1 (255), was upregulated with DMPA use. 
Zalenskaya (35) and Quispe Calla et al. (256, 257) also reported a DMPA-associated 
downregulation of Desmoglein-1, both at the gene and protein level, in human (35, 256) and 
mice (256, 257) tissues, and Zalenskaya et al. also observed an upregulation of CAPN14. In 
mice, a DMPA-associated decrease in expression of Desmoglein-1 promoted increased 
susceptibility to intravaginal HSV-2 infection and induced enhanced genital mucosal 
permeability in their experimental mouse model, indicating that decreased desmosomal 
function influences permeability of the epithelium. 
 
There are several other striking similarities in the results of the study by Zalenskaya et al. and 
ours (35). They also observed DMPA-associated regulation of epithelial barrier genes and 
corresponding biological processes involved in epithelial barrier development. The similar 
results are even more interesting considering the large differences between their study and 
ours including method (micro-array whole-genome transcriptome profiling vs. RNA-seq), 
study population (North American non-sex workers vs. FSWs in a HIV-endemic area) and 
study design (longitudinal vs. cross-sectional). Also, they studied short term (6 weeks) use of 
DMPA, whereas the study population in our study had been using DMPA for at least 6 
months. 
 
Limitations include that we are lacking data on time since last injection of DMPA, as well as 
of serum measurements of MPA. Several recent studies have demonstrated a dose-dependent 
effect of MPA on the genital epithelium (162, 257), further highlighting the benefit of 
evaluating MPA concentrations. Another limitation in the study is the differences in “years in 
sex work” and “age” between the DMPA vs. control group, which may influence the results. 
In addition, the imaging data on Desmoglein-1 needs further analysis. We also used CD4+ 
cells as a proxy for HIV target cells, but would further like to phenotype such cells using 
additional markers and co-receptors for HIV, such as CCR5 and C-type lectin rectors. In 
addition, mRNA from the entire ectocervical biopsy was isolated and sequenced and the 
varying proportions of epithelium/submucosa in the biopsies could potentially bias the results. 
Also, we cannot know exactly from which cells the transcripts originate. This would however 
be possible using single cells RNA-seq. 
 
In conclusion, our transcriptional profiling and imaging data reveal decreased epithelial 
barrier integrity and higher immune activation in the ectocervical mucosa of women using 
DMPA. Our results further suggest that the degradation of proteins essential for desmosomal 
function is one possible mechanism that contributes to this decreased ectocervical tissue 
integrity. Critically, these combined mechanisms may lead to increased HIV susceptibility in 
women using DMPA. 
 
38 
4.1.3 Drivers of sex hormone related changes to HIV susceptibility factors 
 
Combined, the results from Paper 1 and 4 help elucidate potential mechanisms of how 
endogenous and exogenous female sex hormones influence the lower FGT with focus on 
factors important for HIV-susceptibility. The studies differ in design and explore different 
aspects of how endogenous and exogenous sex hormones act in a complex context. Important 
factors that need to be taken into account when interpreting data on hormonal influence 
include presence of plasma serum proteins, pharmacokinetic aspects and affinity of the 
respective compound to different steroid receptors (reviewed in (110)). Other aspects that will 
influence the effect of sex hormones are local tissue concentration of the hormone, which can 
vary from serum concentrations (261), distribution of receptors in different tissues, cross-talk 
between receptors and presence of other receptor-ligands. In addition, the endogenous 
production of female sex hormones is dependent of the intertwined hypothalamic-pituitary-
adrenal and hypothalamic-pituitary-gonadal axis, that is regulated at each of the anatomical 
levels (hypothalamus, pituitary gland, gonads, adrenal glands) with various feed-back loops. 
In short, it is an extremely complex system and it is outside the scope of this thesis to go into 
details of each of the above mentioned aspects. Here, I will give a brief overview of the 
possible mechanisms that drive the phenotypes observed in Paper 1 and Paper 4. 
 
In Paper 1, we studied the fluctuations in exogenous hormones over the menstrual cycle. The 
largest effects were seen in the ovulatory phase (high estradiol, low progesterone) as 
compared to the luteal phase (medium/high estradiol, high progesterone). It is important to 
keep in mind that the observed effect is the combined effect of these hormones, and most 
likely several other factors. The current study design does not allow determination of which of 
these hormones is the strongest influencer or “driver”. However, it can be speculated whether 
high levels of estradiol exert a protective effect on the genital mucosa against HIV-
acquisition, as outlined below. Studies in non-human primates indicate that local and systemic 
estrogen treatment is associated with a thicker vaginal epithelium and decreased susceptibility 
to intravaginal SIV-challenge (140, 141). Post-menopausal women, with low levels of 
estradiol but also progesterone, show a thinner genital epithelium and increased HIV-
replication in ectocervical tissues as compared to pre-menopausal women (131). However, 
epithelial thickness and HIV-susceptibility were increased by a vaginal estradiol-containing 
cream. Another potential protective mechanism of estradiol is that estradiol is believed to be 
the main driver for shifting the cervicovaginal microbiome composition to beneficial 
Lactobacillus-dominance (262), at least in part by promoting glycogen in the genital 
epithelium, which in turn can support Lactobacillus (263). In additional, both estradiol and 
progesterone can have profound effects on immune functions in both the upper and lower 
FGT (reviewed in (109)), which might affect HIV-susceptibility. 
 
It has also been proposed that the hypoestrogenism induced by DMPA may contribute to the 
increased HIV-transmission in DMPA-users (reviewed in (264)). Importantly, progestins 
exert varying effects on endogenous estradiol production, with DMPA inducing the most 
pronounced suppression of estradiol among several progestins. Interestingly in our Paper 4, 
several of the most significant genes upregulated in DMPA users have previously been shown 
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to be regulated by estrogen, and it can be speculated whether estrogen may drive the effects 
observed in the genital epithelium. However, this needs to be further explored, and serum 
estradiol concentrations would be useful for this. 
 
In addition to the proposed effect of hypoestrogenism, the effect of DMPA on HIV-
susceptibility can also be mediated by the active progestin MPA. As mentioned previously, 
MPA show high affinity not only to the PR but also to the GR, and act as a partial to full GR-
agonist (265). This is in contrast to other progestins and endogenous progesterone. It has been 
suggested that such GR-activity modulate HIV-acquisition and pathogenesis (139). The GR-
mediated effect on HIV-susceptibility is supported by several studies (139, 266, 267), 
including a recent study showing that the progestin MPA, but not NET (used in the injectable 
contraceptive NET-EN) enhanced R5 tropic HIV-replication in a genital explant model, and 
that this effect was likely mediated by the GR (267). In summary, the effect of DMPA on the 
FGT mucosa is most likely mediated by a combination of DMPA-induced hypoestrogenism 
and the effect of MPA, acting via the PR and/or GR to varying degrees. 
4.2 THE USE OF A GENITAL EXPLANT MODEL TO EVALUATE THE EFFECT 
OF SEMINAL PLASMA ON INFLAMMATION AND HIV-TRANSMISSION IN 
THE FGT 
 
The majority of new HIV infections in women is due to deposition of semen from HIV-
infected men in the vagina during sexual intercourse (5), but the initial events of HIV-
transmission in the FGT remain largely unknown, partly because of lack of adequate model 
systems (268). Previous studies indicate that semen deposition induce an inflammatory 
response and neutrophil accumulation in the FGT (99, 100), but it remains largely unknown 
how this affects HIV-susceptibility. Therefore, in Paper 2 we used a genital explant model to 
evaluate the effect of seminal plasma on the immunological milieu and HIV-replication in the 
FGT. 
 
In order to evaluate how seminal plasma affects the immunological milieu in the genital 
mucosa, ectocervical explants from healthy donors were exposed to seminal plasma. When 
compared to donor-matched untreated explants, incubation with seminal plasma induced an 
increase for all cytokines (IL-6, TNF, CCL5, CCL20, CXCL1, CXCL8) except for IL-1a and 
IL-10, as measured by bead-based immunoassay in culture medium. When examining the 
transcription of genes corresponding to the measured cytokines by quantitative real-time 
polymerase chain reaction, we observed matching transcription and protein expression for 5 
of the 8 cytokines assessed by both methods. For the majority of cytokines and conditions, the 
addition of the cyclooxygenase-inhibitor indomethacin did not significantly alter the cytokine 
response, suggesting that the seminal plasma-induced response is not affected by endogenous 
prostaglandin production. 
 
To test if we could recapitulate the influx of leukocytes to the mucosa after coitus, peripheral 
blood leukocytes were incubated with culture medium from donor-matched untreated and 
seminal plasma-treated explants in a transwell system. In comparison to culture medium, 
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seminal plasma-treatment increased transmigration of total leukocytes, neutrophils and 
monocytes, but not lymphocytes. Further analysis of receptors on transmigrated monocytes 
show a downregulation of the chemokine receptor CCR5, indicating that the production of the 
CCR5 ligand CCL5 (RANTES) in seminal plasma-treated explants could account for 
recruitment of monocytes. 
 
Previous studies indicate that incubation of isolated cells together with semen and/or seminal 
plasma is toxic (102, 103), and we therefore wanted to evaluate cell viability in our model. 
Apoptosis and necrosis was determined by measuring the expression of Annexin V and the 
binding of an amine-reactive dye in individual cells isolated from explants after incubation 
with either seminal plasma or culture medium only, using flow cytometry. There was no 
difference in the expression of these markers after treatment with seminal plasma in both 
leukocytes (CD45+) and non-immune cells (CD45-), whereas cells from explants incubated 
with the apoptosis-inducing drug camptothecin showed a distinct staining pattern. To further 
evaluate the effect on seminal plasma on tissue viability, an in situ analysis of chromatin 
fragmentation was performed, revealing a few apoptotic cells in the most apical epithelial 
layers of the epithelium as well as shedding of epithelial layers. There was no difference in 
explants treated with seminal plasma vs. controls, indicating that seminal plasma does not 
induce apoptosis in our model. 
 
Since genital inflammation is associated with increased HIV-susceptibility in vivo (14, 92) 
and it has been suggested that semen can impact HIV-transmission (269), we wanted to 
evaluate how seminal plasma induced inflammation affected HIV transmission in our model. 
Donor-matched untreated and seminal plasma-treated explants were infected with CCR5-
tropic laboratory-adapted virus HIV-1BaL and selected transmitter/founder (T/F) HIV-1 
molecular clones. Productive HIV-infection was determined by the release of HIV core 
protein p24gag measured over time in culture medium supernatant as well as HIV-1 DNA in 
explants harvested at the end of culture. For the T/F strains, productive HIV-1 infection was 
not achieved, regardless of culture conditions. For HIV 1BaL, treatment with seminal plasma 
significantly increased the cumulative production of p24gag in culture medium. This was 
observed both when first incubating explants with seminal plasma and then adding the virus-
inoculum, as well as when mixing seminal plasma and virus. We also observed increased 
levels of HIV-1 DNA in seminal plasma-treated vs donor-matched untreated explants. 
Treatment of explants with the anti-retroviral drug lamivudine as a negative control showed 
constant decline of p24gag production in culture medium supernatant and very low levels of 
HIV-1 DNA in explants. 
 
To summarize, we observed a pro-inflammatory reaction as well as increased HIV-1 
infectivity in response to seminal plasma in an ectocervical explant model. Our results of 
elevated pro-inflammatory cytokines in response to seminal plasma/semen are in concordance 
with previous studies in cell lines and primary genital cells (270, 271) and a genital explant 
study (272)). The in vivo human studies are limited, but Sharkey et al. demonstrated an 
increased mRNA expression in human ectocervical biopsies before and after unprotected 
vaginal coitus for several pro-inflammatory cytokines (100). Interestingly, such increase was 
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not observed after protected coitus, supporting our results that it is the semen or derivates 
thereof (such as seminal plasma) that mediate such increase in cytokines. In contrast, another 
study revealed an overall lack of increase in pro-inflammatory cytokines in genital secretions 
after unprotected coitus (101). 
 
An important limitation is that due to the lack of explant polarization, the model does not 
mimic the exact route of HIV-transmission in vivo. However, the detection of cells harboring 
HIV RNA in explants harvested at day 18 post-infection suggests that this system could be 
used to study the pool of HIV-founder cells and their implication in the local response to 
biological as well as pharmacological treatment. Interestingly, productive HIV 1-infection 
was only observed for HIVBaL but not T/F HIV-1 clones, highlighting differences between 
strains and experimental models of HIV infection. Importantly, incubation of explants with 
seminal plasma as evaluated after 24 hour culture, did not seem to induce cell toxicity in our 
model, in contrast to studies in isolated cells (102, 103). In addition, the genital explant model 
described above is flexible and open to modifications. Partially intact tissue architecture, 
absence of seminal plasma-induced toxicity and flexibility of the model support the suitability 
of using genital explants to evaluate the safety and efficacy of microbicides and other local 
applications in the FGT in the context of unprotected sex beyond HIV infection. 
4.3 THE GENITAL PROTEOME OF HIV-SERONEGATIVE WOMEN LIVING IN 
HIV-SERODISCORDANT RELATIONSHIPS 
 
Studies of HIV-serodiscordant couples can aid our understanding of natural relative resistance 
noted in some high-risk groups as well as the immune response evoked by continuous HIV 
exposure. Previous studies have identified both elevated (57, 62, 63, 178, 179) and decreased 
(183, 192) levels of inflammatory proteins (such as several cytokines) and anti-inflammatory 
anti-proteases in the FGT. A low baseline immune activation (so called “immune 
quiescence”) has also been proposed as a mechanism of protection against HIV-infection 
(174). However, these findings are primarily based on FSWs and other cohorts with high 
levels of unprotected sex and STIs/clinical inflammation. In contrast, in the HIV-
serodiscordant cohort in Paper 3, we observed low levels of STIs/clinical inflammation and 
high levels of protected sex. We therefore hypothesized that their genital protein composition 
would be similar to that of the general population in the same geographical area. To 
characterize the genital proteome of women living in HIV-serodiscordant relationships, CVS 
from these women were assessed by a high-throughput bead based protein profiling technique 






Figure 7. Overview of study setup. A. Cervicovaginal secretions from women in HIV-serodiscordant 
relationships were collected at three time points, and from controls (women in HIV-seroconcordant 
negative relationships) at one time point. B. A total of 332 antibodies directed towards 172 unique proteins 
were coupled to color-coded magnetic beads and mixed in a suspension bead array. C. Beads and samples 
were incubated and levels of proteins bound to the beads were measured using Luminex. D. Protein levels 
were subjected to univariate as well as data driven multivariate statistical analysis. The most interesting 
proteins from the univariate and multivariate analysis were stained for in genital tissues, resulting in a total 
of five proteins consistently associated with the HIV-serodiscordant phenotype that were also visualized in 
genital tissues. Original version of figure was originally published in (273), adapted and reprinted with 
permission. 
 
To identify proteins associated with the serodiscordant phenotype, the protein composition in 
CVS was compared to the control group, revealing 24 proteins found at higher levels (p<0.05) 
in the serodiscordant group. These included serine proteases (KLK10, PLG), protease 
inhibitors (SPINK5, SERPINB1/5), proteins involved in epithelial barrier function (SPRR3, 
SPINK5) and immune activation/inflammation (CAPG, KLK10, S100A9, IL18, CXCL9, 
CCL21). Of these, 4 (CAPG, KLK10, TTR, SPRR3) passed multiple comparison corrections. 
The data was adjusted to account for differences between study groups for several 
demographic parameters, revealing even stronger associations with the HIV-serodiscordant 
phenotype for the most significant proteins. Data-driven multivariate analysis was performed 
in order to reveal potentially intersecting biological relationships, identifying two additional 
proteins (the antiproteases PI3/elafin and CSTB) as associated with the serodiscordant 
phenotype. 
 
Next, we wanted to evaluate the expression of the most interesting proteins in genital tissues 
in order to confirm their presence in the FGT. The proteins chosen for immunohistological 
staining were the most significant proteins identified in the univariate analysis (CAPG, TTR, 
KLK10, SPRR3), and two additional proteins (PI3 and CSTB) identified using data driven 
modeling. All proteins except TTR were positively stained for in genital tissues; SPRR3, 
KLK10, CSTB and PI3 were expressed in the epithelium and CAPG in the submucosa of the 
cervix and vagina. 
 
In conclusion, by using a combination of different methods, we identified five proteins 
(CAPG, KLK10, SPRR3, CSTB and PI3) that were associated with the serodiscordant 




In contrast to our original hypothesis that the cervicovaginal proteome of HIV-serodiscordant 
women would be similar to that of control women, we observed a distinct genital proteome 
profile of altered levels of proteins involved in inflammation and epithelial barrier function. In 
the HIV-serodiscordant group, both serine proteases (KLK10, PLG) and serine/cystein 
protease inhibitors (PI3, SPINK5, CSTB, SERPINB1/5) were elevated. PI3 (185, 274) and 
CSTB (275) have anti-HIV in vitro, and increased levels of several protease inhibitors, 
including PI3 and CSTB, have been identified in FSW cohorts previously as potential 
correlates of protection (57, 62, 63, 185). Serine protease inhibitors play important roles in 
regulating inflammation and tissue development and can contribute to an anti-inflammatory 
local environment (64, 276). However, there is a constant balance in the body between 
proteases and anti-proteases, and it is the net effect of these opposing forces as well as other 
pro/anti-inflammatory proteins and molecules that will determine the local immunological 
effect and might contribute to altered HIV-susceptibility. In addition, as mentioned 
previously, an inflammatory response will be followed and counteracted by an anti-
inflammatory response, and this is a continuum. Indeed, in the serodiscordant group we 
observed altered levels of both “pro” and “anti”-inflammatory proteins, once again 
highlighting the difficulties on determining the net effect on the mucosa based on protein 
expression. In conclusion, we can conclude that proteins involved in genital inflammation and 
immunity are altered in the HIV-serodiscordant group, but the current study design does not 
allow more detailed examination of the combined effect of these protein on the female genital 
mucosa.  
 
In addition to their above mentioned function in inflammation, several serpins and other anti-
proteases are involved in maintenance of the epithelial barrier (276-279). We also observed 
SPRR3, a structural protein in the cornified envelope of the epidermis (280), to be elevated in 
the serodiscordant group. In addition, these proteins showed positive staining in genital 
tissues, indicating that they are present and possibly have a function in the FGT. Alterations to 
epithelial barrier integrity and function are suggested to be associated with altered 
susceptibility to HIV-infection (36, 40, 42, 51, 65), at least in part because of easier access of 
the virus to potential HIV-target cells in the epithelium and submucosa. Collectively, these 
data suggest that epithelial barrier integrity and/or function is altered in the HIV-
serodiscordant group, but our study design does not allow further exploration of such 
epithelial barrier-associated alteration in HIV susceptibility. 
 
Several limitations exist, including the low sample size and lack of longitudinal samples for 
control women. Another limitation is the difference between groups for several demographic 
parameters, which could potentially bias the results. However, these potential confounders 
were thoroughly adjusted for using different statistical methods, revealing that the association 
between the HIV-serodiscordant phenotype and the most statistically significant proteins 
remained. Yet, it is possible that these and other unknown confounders could affect the 
results. The menstrual cycle (45, 248) and the cervicovaginal microbiome (52) can influence 
the protein composition in the FGT, but unfortunately we are lacking data on these factors. 
Further, a limitation of ours and other proteomic studies is that, since no functional analyses 
were performed, our results are purely observational and we cannot decipher biological 
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activity in the adjacent genital tissue. Not only are the functions of proteins complex and 
should be interpreted together with other proteins, including proteins with opposing effect, but 
depending on if proteins are secreted basolaterally or apically, they can exert varying effect on 
the underlying tissues (281). However, we confirmed the presence of the most interesting 
proteins in genital tissues, indicating that they perform a function in the FGT. 
 
In conclusion, we observed a distinct proteomic profile of altered levels of proteins involved 
in inflammation and epithelial barrier function in a cohort of HIV-serodiscordant women with 
low clinical inflammation and high frequencies of safe sex practices. Our findings 
complement studies in FSW cohorts and cohorts with high levels of clinical inflammation, 
and our finding need to be taken into consideration when designing and interpreting results 
from clinical studies in settings with high HIV-prevalence. 
4.4 EVALUATING THE FEASIBILITY OF A HIGH-THROUGHPUT BEAD BASED 
ASSAY IN IDENTIFYING PROTEINS IN GENITAL SECRETIONS 
 
A secondary aim of Paper 3 was to evaluate the feasibility of using a high-throughput bead-
based protein profiling method when assessing genital secretions. The majority of proteomic 
studies in genital secretions have been conducted using MS-based methods, and although the 
use of antibody-based methods such as ELISA is common in studying a limited numbers of 
proteins simultaneously, the use of high-throughput antibody-based affinity methods are rare. 
 
To evaluate antibody selectivity, more than one antibody directed to the same protein (“paired 
antibodies”) were used for several proteins. For the 24 proteins identified to be associated 
with HIV-serodiscordant status in the univariate analysis, 5 were evaluated using paired 
antibodies. For paired antibodies generated using the same immunogen, we observed a 
spearman’s rho of 0.87-0.99 (range), whereas for antibodies generated towards different 
immunogens (non-overlapping amino-acid sequence), the spearman’s rho was slightly lower 
at 0.73-0.84 (range). 
 
To validate the findings of the affinity bead based analysis using another protein identification 
technique, CVS samples were analyzed by both affinity-based protein profiling and a tandem 
MS-based method. 79 antibody/proteins pairs were identified in 85 matching samples, and the 
median Spearman’s rho for these was 0.46 (range -0.35– 0.77). For the five proteins 
consistently identified in the first part of the manuscript as being associated with the HIV-
serodiscordant phenotype, clear positive correlations were observed for SPRR3, KLK10 and 
PI3 (range rho 0.47-0.53, BH adj. p 0.0003), whereas CAPG and CSTB exhibited weak 
correlations (range rho 0.06-0.24, BH adj p>0.05). 
 
In general, we observed a medium high correlation between the bead-based protein profiling 
method and a MS based method. The strength of the correlation varied for different proteins 
and also for antibodies directed towards the same protein, which is not surprising since the 
antibodies are polyclonal and therefore bind with varying affinities to epitopes with likely 
various degree of exposure. There are several possible explanations to the discrepancies 
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between the two methods, including that both methods measure relative, as compared to 
absolute, quantification of protein content. In addition, the HPA antibodies used have been 
validated in microarray plates but not in aqueous solutions, and since the function of 
antibodies is context dependent (282), we cannot be certain of antibody specificity in complex 
environments such as CVS. Furthermore, the natural configuration of the protein and post-
translational modifications may hide epitopes, which also could affect antibody affinity. 
However, we observed high correlations between antibodies directed towards non-
overlapping sequencing of the same protein, indicating that the intended target protein was 
identified. 
 
To conclude, the high correlation between paired antibodies as well as a medium high 
correlation between separate proteomic techniques indicate this it is feasible and appropriate 





5 CONCLUDING REMARKS 
 
The studies presented in this thesis show that female sex hormones, HIV-serodiscordant status 
and seminal plasma induce changes to the female genital mucosa that may alter the 
susceptibility to HIV. 
• The fluctuations of female sex hormones over the course of the menstrual cycle exert a 
profound effect on the cervicovaginal proteome. The largest change is observed during 
the short ovulatory phase, which is characterized by a decrease in inflammatory markers 
and increase is markers of epithelial barrier integrity (Paper 1). 
• The cervicovaginal microbiome in healthy Swedish women is dominated by 
Lactobacillus and is not affected by the cycling of endogenous sex hormones over the 
course of the menstrual cycle (Paper 1). 
• Sex-hormone induced fluctuations in the cervicovaginal proteome over the course of the 
menstrual cycle might be exacerbated in women with non-Lactobacillus dominant 
microflora (Paper 1). 
• The progesterone-high luteal phase and use of the progestin-containing injectable 
contraceptive DMPA enhance immune activation in the FGT and decrease epithelial 
barrier integrity (Paper 1 and 4). 
• The use of DMPA is associated with degradation of proteins essential for desmosomal 
function and a thinner superficial epithelial layer in the ectocervical epithelium (Paper 
4). 
• Seminal plasma induces genital inflammation and increases HIV-infectivity as 
demonstrated in an ectocervical genital explant model (Paper 2). 
• The ectocervical genital explant model is a useful platform to decipher the intial events 
of HIV-transmission and the effect of seminal plasma on such intial events (Paper 2). 
• HIV-seronegative women living in HIV-serodiscordant relationships show alterations in 
the genital expression of proteins involved in inflammation and epithelial barrier 
integrity (Paper 3). 
• A high-throughput bead-based set up is a suitable method for evaluating proteins in 
genital secretions, and there is a medium high correlation with a mass spectrometry-





6 FUTURE PERSPECTIVES 
 
In 2002 the United Nations Secretary General Kofi Annan said “In Africa, AIDS has a 
woman’s face”. Almost 20 years later, this still holds true. The scientific community owe is to 
the millions of women living with and at risk of HIV to use funds wisely to develop HIV 
prevention strategies accessible to all. Despite almost 40 years of research, there is still no 
HIV-vaccine in clinical use. In wait for an effective HIV-vaccine, we might have to put our 
hopes to other preventive measures, especially female-controlled preventive measures, such 
as for example microbicides. 
 
With this thesis, I aimed to characterize mucosal factors within the FGT to better understand 
potential molecular mechanisms associated with altered HIV-susceptibility. This knowledge 
could aid in identifying genital mucosal signatures associated either with protection or 
increased risk of HIV-infection. Such mucosal signatures could help guide the preventative 
field, perhaps women with a certain signature benefit from one type of preventative measures 
as compared to other women. If we could stratify women based on mucosal markers, it might 
be possible to personalize preventative interventions aimed at reducing HIV-transmission. In 
addition, by identifying a protective mucosal signature, the scientific field may find solutions 
how to pharmacologically induce such mucosal state. 
 
Effective, safe and widely available contraceptives are a global health priority, and reports 
about an increased risk of HIV-acquisition associated with some HC must be taken very 
seriously. In order to aid in the development of safe contraceptives, it is essential to 
understand potential underlying mechanisms of HC as well as endogenous female sex 
hormones. Ideally, HC and HIV-prevention compounds could be combined in one 
formulation to facility use. Therefore, it is especially important to investigate the effect of HC 
in populations that would be targets for HIV-prevention methods, such as FSW, as we have 
done in Paper 4. Studies of the populations intended for preventative measures can reduce 
geographical, ethnical and cultural differences that might otherwise have influenced the 
results. 
 
The -omics field has exploded in the past years, and it offers great advantages in trying to 
achieve a comprehensive picture of the complex mucosal milieu in the FGT. In this thesis, we 
used proteomics, transcriptomics and gene sequencing techniques to study the effect of sex 
hormones and HIV-serodiscordant status on the FGT. There are advantages and limitations 
with each of these -omics, and I believe that the future lies in the combination of data from 
several -omics, so called multi-omics. Multi-omics has the potential to identify novel 
interactions that are not identified using single -omics, and is especially suitable for studying 
very complex systems, such as the immune system in the FGT. In a continuation of Paper 4, 
we have performed protein profiling on matching genital samples with the aim of identifying 
potential intersecting relationships between the transcriptome and proteome in order to more 




The studies in this thesis, except for Paper 3, are of an observational nature. In my thesis, I 
have discussed the challenges of interpreting observational studies to decipher the net effect 
on the mucosa as well as the need for follow-up functional studies. The genital explant model 
presented in Paper 2 can aid in such studies, for example by studying the effect of female sex 
hormones or different microbial species on HIV-transmission. This explant model is also an 
excellent tool in evaluation of microbicides. In the future, I hope to experimentally assess the 
role of endogenous and exogenous female sex hormones in an explant model. 
 
There is still a long way to go to combat HIV/AIDS, but effective prevention strategies in 
women play a key role and should be considered a global health priority. In the foreseeable 









HIV är ett virus som attackerar kroppens immunförsvar och om viruset förblir obehandlat så 
kan det leda till den dödliga sjukdomen AIDS, då immunförsvaret helt slås ut. Det finns 
mediciner som bromsar utvecklingen av AIDS men det finns inget botemedel och inte heller 
något vaccin. Sedan HIV viruset identifierades på 1980-talet så har det spridit sig över 
världen, och Världshälsoorganisationen uppskattar att det idag finns 38 miljoner smittade, 
majoriteten i södra Afrika. 
 
HIV kan smittas via blodet och över slemhinnor, såsom vid sexuell kontakt. Det finns många 
faktorer som påverkar hur stor risk det är att smittas, såsom typ av samlag, virusnivåer hos 
den smittande individen och samtidiga andra könssjukdomar. Den största delen av nya HIV-
infektioner globalt sker vid oskyddat vaginalt samlag. Det finns mekaniska och 
immunologiska faktorer i genitala slemhinnan som skyddar kroppen mot HIV. Mekaniska 
barriärer är t.ex. det skyddande sekret som täcker slemhinnan samt epitelet, som är den 
yttersta delen av slemhinnan. I sekretet finns det utsöndrade proteiner (äggviteämnen), bland 
annat ifrån immunförsvaret, som kan motverka HIV. Ibland kan viruset, trots dessa 
skyddsbarriärer, ta sig igenom och infektera immunceller i slemhinnan och så spridas vidare i 
kroppen. 
 
I denna avhandling har vi studerat faktorer som påverkar den genitala slemhinnan, samt hur 
dessa kan ha betydelse för smittoöverföring av HIV.  
7.2 DELSTUDIE 1-4 
 
Tidigare studier talar för att hormonvariationer i menscykel kan påverka mottagligheten för 
HIV och att det kan finnas en ökad risk för smitta under den senare delen av menscykeln då 
nivåerna av könshormonet progesteron är som högst. I delstudie 1 samlade vi in slidsekret 
från kvinnor under olika faser i deras menscykel och mätte proteinnivåer i sekreten. Vi visade 
att proteiner som tros ha en skyddade effekt på slemhinnan var allra högst runt ägglossning 
och som lägst före menstruation, dvs. i den progesteron-dominerade fasen. Vi såg även att 
proteiner och molekyler som tyder på inflammation var högre i den fasen. Ökad genital 
inflammation talar också för att risken att smittas av HIV-infektion kan öka, bland annat då 
det kan leda till en ansamling av målceller för HIV. Våra resultat stödjer tidigare studier som 
visar att risken för HIV-smitta kan variera över menscykeln. 
 
Trots många år av forskning kring HIV så är relativt okänt vad som händer initialt i 
genitalslemhinnan vid HIV-smitta, och det beror till viss del på att det saknas bra 
experimentella modeller för att studera detta. Det är heller inte känt hur sädesvätska påverkar 
den genitala slemhinnan och smittoöverföringen av HIV. I delstudie 2 använde vi ett modell-
system där vävnad från livmodertappen exponerades för sädesvätska. Vi kunde påvisa att 
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denna vävnad svarade med genital inflammation och blev lättare infekterad av HIV än vävnad 
som ej exponerats för sädesvätska. Den här studien visar att det är viktigt att inkludera 
sädesvätska som en faktor vid studier av HIV-överföringen. Vi hoppas också att detta 
modellsystem kan användas för att utvärdera skyddande ämnen som kan appliceras på 
slemhinnan för att minska smittoöverföringen, t.ex. mikrobicider. 
 
Runtom i världen finns det individer och grupper som trots exponering för HIV undgått att bli 
smittade, t.ex. vissa kvinnliga prostituerade. En del studier talar för att deras genitala 
immunförsvar skiljer sig från andra kvinnors och kan utgöra ett skydd mot viruset. I delstudie 
3 så undersökte vi en annan grupp kvinnor som är utsatta för HIV-smitta, nämligen kenyanska 
HIV-negativa kvinnor med en HIV-positiv manlig partner. Sådana par kallas serodiskordanta. 
Till skillnad från många grupper av prostituerade som tidigare studerats så har den här 
gruppen låga nivåer av andra riskfaktorer som samtidiga könssjukdomar och de har också en 
hög grad av kondomanvändning. Vi jämförde slidsekretet hos dessa kvinnor med slidsekret 
från HIV-negativa kvinnor med en HIV-negativ partner (kontrollgrupp). Vår hypotes var att 
slidsekretet från kvinnorna i diskordanta par inte skulle skilja sig nämnvärt från kontrollerna. 
Vi kunde dock påvisa skillnader av proteiner involverade i barriärfunktionen av slemhinnan 
samt immunförsvaret, vilket talar för att HIV-negativa kvinnor i serodiskordanta förhållanden 
har en distinkt ”genital profil” som skiljer sig från kvinnor med en HIV-negativ partner. 
Ytterligare studier krävs för att förstå om och hur dessa skillnaderna i dessa proteiner kan 
påverka risk för HIV-infektion. 
 
En del studier tyder på att användningen av vissa typer av hormonella preventivmedel, 
framförallt så kallad p-spruta, är kopplat till ökad risk för att bli smittad av HIV. Orsaken till 
detta är dock okänd och skulle kunna bero på olika riskbeteende vid p-spruta användning 
alternativt mer biologiska effekter som ökar mottagligheten för HIV. I delstudie 4 jämförde 
vi den genitala slemhinnan hos kenyanska kvinnor som använder p-spruta med kvinnor som 
inte använder några hormonella preventivmedel. Hos kvinnorna som använder p-spruta såg vi 
en nedreglering av gener som är viktiga för barriärfunktion, bland annat gener som kodar för 
”klister-proteiner” som normalt sett bidrar till en intakt slemhinna. Dessa kvinnor hade även 
ett tunnare övre lager av slemhinnan jämfört med kontroller. Detta kan tala för att användning 
av p-spruta bidrar till en mer lucker/genomsläpplig slemhinna, och att detta eventuellt kan 
bidra till ökad mottaglighet för HIV-smitta hos dessa kvinnor. Denna kunskap är viktigt dels 
för att förstå hur preventivmedel påverkar slemhinnan och dels för utveckling och rådgivning 




Dessa studier bidrar till att kartlägga faktorer som påverkar den genitala slemhinnan och som 
kan ha betydelse för HIV-smitta hos kvinnor. Den kunskapen kan förhoppningsvis bidra till 
att utveckla förebyggande åtgärder för att minska smittspridningen av HIV, såsom t.ex. 
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